



**2025 OSMA Annual Meeting  
Resolution Committee One  
Resolutions 1-27, OSMA Policy Sunset Report**

**#1 - IMG, WPS, SPS Seats on Council**

**#2 - Procedure for Approval for Recording of OSMA Meetings**

**#3 – Support for Environmental Initiatives**

**#4 - WITHDRAWN BY SPONSORS**

**#5 - Limits on Numbers of Resolutions**

**#6 - Physician Exercise of Conscience and Sound Medical Ethics**

**#7 - Supporting and Promoting AMA Member Physicians and Physician Spouses as Candidates for Local, State and Federal Office**

**#8 - Ohio License and Medical Practice in Ohio Required for Physician Collaborators/Supervisors of Advanced Practice Providers**

**#9 - Physician Led Health Care Teams**

**#10 - Physician-Led Healthcare Teams**

**#11 - Opposing the Use of Physician Associate**

**#12 - Regulating Practitioners that Practice Non-Conventional Medicine (Herbalists, Naturalists, Homeopaths, Ayurveda, Asian Herbal Medicine)**

**#13 - Mobilizing Healthcare Professionals to Address Police Violence as a Public Health Crisis**

**#14 - Physicians Engaged in Non-Violent Civil Protest**

**#15 - Support for Diversity, Equity, and Inclusion in Ohio Medical Schools**

**#16 - Gender-Identification on State Government IDs**

**#17 - Gender Dysphoria**

**#18 - Support for Statewide Tracking of and Control Mechanisms for Health Care Expenditure Growth that Promote Primary Care**

**#19 - Mental Health Disclosures Policy for Medical Applicants**

**#20 – Mandating Child-Proof Packaging on Marijuana Products Sold Legally in the State of Ohio**

**#21 – Marijuana Guidelines Following Ohio Legalization**

**#22 – Support for Education on Intimate Partner Violence Screening with Medical Students, Residents, and Physicians**

**#23 – Registry for Potential Side Effects of GIP & GLP-1 Medications**

**#24 – Streamlining Annual Compliance Training for Physicians**

**#25 – Physician Owned Hospitals**

**#26 – Seat Belt Laws**

**#27 – Advancing Public Health Protections Against Per- and Polyfluoroalkyl Substances (PFAS)**

**OSMA Policy Sunset Report**



47 members, and 6) to represent the unique interests of women members of the OSMA.”<sup>2</sup>;  
48 and

49  
50 **WHEREAS**, OSMA Senior Physicians Section Bylaws Chapter 1 states “The  
51 purpose of this section is to 1) provide an additional means for section members to  
52 participate in OSMA policy making and other activities, 2) enhance OSMA outreach,  
53 communication and interchange with members represented in the section, 3) maintain  
54 effective communications between the section and the OSMA, 4) promote OSMA  
55 membership growth, 5) promote professional development and education of its  
56 members, and 6) to represent the unique interests of senior members of the OSMA.”<sup>3</sup>;  
57 and

58  
59 **WHEREAS**, OSMA International Medical Graduates Section Bylaws Chapter 1  
60 states “The purpose of this section is to 1) provide an additional means for section  
61 members to participate in OSMA policy making and other activities, 2) enhance OSMA  
62 outreach, communication and interchange with membership sections represented in  
63 OSMA sections, 3) maintain effective communications between the sections and the  
64 OSMA, 4) promote OSMA membership growth, 5) promote professional development  
65 and education of its members, and 6) to represent the unique interests of international  
66 medical graduate members of the OSMA.”<sup>4</sup>; and

67  
68 **WHEREAS**, OSMA Women (draft), Senior, and International Graduate  
69 Physicians Section Bylaws state that amendment of their own section bylaws is “subject  
70 to the approval of the Council of the Ohio State Medical Association prior to  
71 implementation.”<sup>2, 3, 4</sup>; and

72  
73 **WHEREAS**, including member seats from the OSMA demographic sections (e.g.  
74 Young Physicians Section, Medical Student Section, etc.) on the Council guarantees an  
75 opportunity for representation of these sections’ unique interests; and this cannot be  
76 ensured through representation from the geographical councilor districts; and

77  
78 **WHEREAS**, the Women Physician Section, Senior Physician Section, and  
79 International Medical Graduates Section do not have a representative on the OSMA  
80 Council; and therefore

81  
82 **BE IT RESOLVED**, that the OSMA Bylaws shall be updated so that the Council  
83 shall additionally include one (1) member of the Women Physician Section, one (1)  
84 member of the Senior Physician Section, and one (1) member of the International  
85 Medical Graduates Section. The bylaws of each of these sections shall be updated  
86 (according to established procedure) to define the process of electing their  
87 representative member to the Council; and be it further

88  
89 **RESOLVED**, that the OSMA Bylaws shall be updated so that the Council shall  
90 include four (4) At-Large Councilors, rather than the current six (6) At-Large Councilors.

91  
92 **Fiscal Note:** Less than \$500 (Sponsor)  
93 Less than \$500 (Staff)

94

95 **References**

96

97 1. Ohio State Medical Association Constitution And Bylaws (Amended April 2024)

98 2. Bylaws of the OSMA Women Physicians Section

99 3. Bylaws of the OSMA Senior Physicians Section

100 4. Bylaws the OSMA International Medical Graduate Physician Section



46 **SECTION 7. PROCEDURE FOR APPROVAL OF RECORDING OSMA**  
47 **MEETINGS.**

48  
49 ANY RECORDING OF OSMA MEETINGS OF ITS HOUSE OF  
50 DELEGATES, EXECUTIVE COUNCIL, EXECUTIVE COUNCIL  
51 SUBCOMMITTEES, SECTIONS, AND OTHER COMMITTEES CREATED  
52 BY THIS CONSTITUTION AND BYLAWS IS PROHIBITED UNLESS AS  
53 PROVIDED BELOW.

54  
55 THIS PROHIBITION DOES NOT APPLY TO OSMA STAFF MEMBERS  
56 (OR THEIR DESIGNEES) FOR THE PURPOSE OF RECORDING A  
57 MEETING TO PRODUCE WRITTEN MINUTES OR TO REPRODUCE  
58 THE MEETING ELECTRONICALLY FOR MEETING MEMBERS TO  
59 LATER REVIEW.

60  
61 THIS PROHIBITION DOES NOT APPLY TO OSMA GEOGRAPHICAL  
62 DISTRICT MEETINGS. EACH DISTRICT LEADERSHIP SHALL  
63 DETERMINE HOW BEST TO ADDRESS RECORDINGS WITHIN ITS  
64 VOTING AND GOVERNANCE STRUCTURE.

65  
66 A BRIEF SUMMARY OF THIS SECTION SHALL APPEAR ON ALL  
67 APPLICABLE MEETING AGENDAS.

68  
69 IF A VIOLATION OF THIS SECTION OCCURS, THE OSMA MAY TAKE  
70 SUCH ACTION AS NECESSARY, INCLUDING BUT NOT LIMITED TO:

- 71  
72 (1) REQUIRING SUCH PERSON TO IMMEDIATELY CEASE AND  
73 DELETE THE RECORDING  
74  
75 (2) REQUIRING SUCH PERSON TO IMMEDIATELY LEAVE THE  
76 MEETING  
77  
78 (3) BANNING SUCH PERSON FROM FUTURE OSMA MEETINGS  
79  
80 (4) REMOVING SUCH PERSON FROM ANY OSMA COUNCIL,  
81 SECTION, COMMITTEE, OR OTHER OSMA OFFICE,  
82 PURSUANT TO CHAPTER 6, SECTION 9 OF THE OSMA  
83 BYLAWS  
84

85 EXCEPTIONS MAY BE MADE ON A CASE-BY-CASE BASIS, AND ONLY  
86 UPON APPROVAL BY ALL OF THE FOLLOWING:

- 87  
88 (1) THE OSMA PRESIDENT, OR IN THE PRESIDENT'S ABSENCE THE  
89 PRESIDENT ELECT;  
90  
91 (2) ALL MEMBERS OF THE MEETING BODY; AND

92  
93 (3) OSMA LEGAL COUNSEL  
94  
95  
96  
97

98 **Fiscal Note:** \$ 0 (Sponsor)  
99 \$ 500 (Staff)

100  
101 **References:**

102  
103 Section V, OSMA Constitution and Bylaws  
104  
105

106 **ARTICLE V MEETINGS**

107 **Section 1. Annual Meeting.** This Association shall hold an Annual Meeting at  
108 which there shall be a meeting of the House of Delegates.

109  
110 **Section 2. Time and Place of Annual Meeting.** The time and place for holding  
111 each Annual Meeting shall be fixed by the Council of this Association and Delegates  
112 shall be physically present except when the OSMA Council determines that  
113 extraordinary circumstances exist that make it impossible or inadvisable for delegates  
114 to be physically present.

115  
116 **Section 3. Special Meetings.** Special meetings of the House of Delegates shall  
117 be called by the President or other officer upon a two-thirds (2/3) vote of the Council or  
118 upon filing, with the Chief Executive Officer of this Association, a petition duly  
119 authorized and signed by at least fifty active members residing or practicing in at least  
120 two OSMA districts. Within ten (10) days after such action of the Council, or the filing  
121 of such petition, the Chief Executive Officer shall give written notice to the members of  
122 the House of Delegates setting forth the purpose or purposes of such meeting and  
123 specifying the time and place thereof, in no event shall the meeting be less than twenty  
124 (20) days nor more than sixty (60) days after the mailing of such written notice.  
125

126 **Section 4.** At least ten (10) days advance notice of meetings of members shall  
127 be published in print or shall be given by use of authorized communications equipment  
128 as defined in Section 5.

129  
130 **Section 5.** Members and Councilors may attend and participate in all meetings of  
131 this Association, including participation by casting any vote that the member or  
132 Councilor is qualified to cast, in person or via the use of authorized communication  
133 equipment if use of such equipment is approved by the Council. Any member  
134 participating in a meeting via authorized communications equipment shall be  
135 considered "present" at that meeting for all relevant purposes. Any recorded

136 transmission by authorized communications equipment shall be considered "written" or  
137 a "writing" for all relevant purposes stated in the Constitution and Bylaws. The Council  
138 shall establish procedures and guidelines for the use of authorized communications  
139 equipment in order to permit the Council to verify that a person is a voting member and  
140 to maintain a record of the person's presence and any relevant vote that person casts  
141 by use of the authorized communications equipment.  
142

143 As used in this section and these Constitution and Bylaws, "authorized communications  
144 equipment" means any communications equipment that provides a transmission,  
145 including, but not limited to, by telephone, telecopy, or any electronic means, from which  
146 it can be determined that the transmission was authorized by, and accurately reflects the  
147 intention of, the member or Councilor involved and, with respect to meetings, allows all  
148 persons participating in the meeting to contemporaneously communicate with each  
149 other.  
150

151 **Section 6. Conduct of Meetings.** Meetings of the Association may be held in person or  
152 by means of authorized communications equipment as defined in this Article if use of  
153 such equipment is approved by the Council except as stated in Section 2 of this Article.  
154 Voting members who are not physically present at a meeting of voting members may  
155 attend the meeting by the use of authorized communications equipment that enables the  
156 voting members an opportunity to participate in the meeting and to vote on matters  
157 submitted to the voting members, including an opportunity to read or hear the  
158 proceedings of the meeting, participate in the proceedings, and contemporaneously  
159 communicate with the persons who are physically present at the meeting. Any voting  
160 member who uses authorized communications equipment is deemed to be present in  
161 person at the meeting whether the meeting is held at a designated place or solely by  
162 means of authorized communications equipment. The Council may adopt procedures  
163 and guidelines for the use of authorized communications equipment in connection with a  
164 meeting of voting members to permit the Association to verify that a person is a voting  
165 member and to maintain a record of any vote or other action taken at the meeting.



47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

**WHEREAS**, Black, Hispanic, and Native American people experience higher rates of negative health impacts with extreme heat events and temperature fluctuations than their White counterparts<sup>7</sup>; and

**WHEREAS**, according to the 2021 Health Value Dashboard, Ohio is ranked 43rd out of 50 states and D.C. on environmental metrics related to air quality, water quality, and toxic substance exposure<sup>3</sup>; and

**WHEREAS**, in an environmental justice policy scorecard, the Northeast-Midwest Institute ranked Ohio as one of the lowest states in the Midwest due to its lack of legislation on environmental justice<sup>4</sup>; and

**WHEREAS**, Michigan’s Department of Environment, Great Lakes, and Energy has an Office of the Environmental Justice Public Advocate with its own funding and staff that is dedicated to advancing environmental justice in the state<sup>8</sup>; and

**WHEREAS**, the Biden-Harris Administration granted \$2 million in funding for environmental justice projects in Ohio through the U.S. EPA’s Environmental Justice Collaborative Problem Solving Cooperative Agreement<sup>9</sup>; and

**WHEREAS**, Ohio House Bill 429, a bill introduced in the 2022 legislative session by Representatives Casey Weinstein and Stephanie Howse, sought to launch environmental justice programs and build clean energy policy that recognizes equity for historically marginalized communities, but it failed in committee<sup>10</sup>; and

**WHEREAS**, the U.S. Attorney for the Southern District of Ohio, Kenneth L. Parker, established a new environmental justice initiative for the district in October 2022 to enforce environmental laws and prosecute violations leading to discriminatory environmental and health impacts<sup>11</sup>; and

**WHEREAS**, the AMA has policies recognizing the harmful impacts to health that environmental pollution and destruction may have and supports the development of environmental committees as well as programs to combat racism (H-65.952; H-135.931; H-135.932; H 135.973; H-135.969; 135-997); and

**WHEREAS**, the OSMA “encourages the development of policy to combat climate change and its health effects in Ohio and to mitigate the undesirable environmental conditions that damage Ohioans’ health” (Policy 27 – 2022); and therefore

**BE IT RESOLVED**, that the OSMA recognizes environmental justice, as defined by the US Department of Health And Human Services in 2024, as the fair treatment and meaningful involvement of people regardless of race, color, national origin, or income in the development, implementation, and enforcement of environmental laws, regulations, and policies; and be it further

93           **RESOLVED**, that the OSMA supports state action to address and remediate  
94 environmental injustice and environmental conditions adversely impacting health,  
95 particularly in marginalized communities.  
96

97 **Fiscal Note:**           \$ (Sponsor)  
98                               \$ (Staff)  
99

100 **References:**

- 101
- 102 1. United States Health and Human Services. “Environmental Justice.” *US HHS*, 4 May  
103 2023, <https://www.hhs.gov/civil-rights/for-individuals/special-topics/environmental-justice/index.html#:~:text=Environmental%20Justice%20is%20the%20fair,laws%2C%20regulations%2C%20and%20policies..> Accessed 1 Nov. 2024.
  - 104  
105
  - 106 2. “Environmental Justice Factsheet.” *Center for Sustainable Systems*, University of  
107 Michigan, 2023, [css.umich.edu/publications/factsheets/sustainability-  
108 indicators/environmental-justice-factsheet](https://css.umich.edu/publications/factsheets/sustainability-indicators/environmental-justice-factsheet). Accessed 30 Nov. 2023.
  - 109 3. Health Policy Institute of Ohio. “2021 HEALTH VALUE DASHBOARD.” *Health Policy  
110 Institute of Ohio*, Apr. 2021.
  - 111 4. Griffin, Nicholas. Scorecard of Environmental Justice Policies in Northeast-Midwest  
112 States. *Northeast-Midwest Institute*, July 2022.
  - 113 5. Lazaroff, Marissa. *The Crossroads of Environmental Racism and Public Housing*.  
114 The Ohio Environmental Council, 2020.
  - 115 6. Kodros, John K., et al. “Unequal Airborne Exposure to Toxic Metals Associated with  
116 Race, Ethnicity, and Segregation in the USA.” *Nature Communications*, vol. 13, no.  
117 1, 1 Nov. 2022, <https://doi.org/10.1038/s41467-022-33372-z>.
  - 118 7. Berberian, Alique G., et al. “Racial Disparities in Climate Change-Related Health  
119 Effects in the United States.” *Current Environmental Health Reports*, vol. 9, no. 3, 28  
120 May 2022, pp. 451–464, <https://doi.org/10.1007/s40572-022-00360-w>. Accessed 30  
121 Nov. 2023.
  - 122 8. A “Office of the Environmental Justice Public Advocate.” *Department of  
123 Environment, Great Lakes, and Energy*, State of Michigan,  
124 [www.michigan.gov/egle/about/organization/environmental-justice](http://www.michigan.gov/egle/about/organization/environmental-justice). Accessed 1 Dec.  
125 2023.
  - 126 9. EPA Press Office. “Biden-Harris Administration Announces \$2 Million for  
127 Environmental Justice Projects in Communities across Ohio as Part of Investing in  
128 America Agenda.” *US EPA*, 24 Oct. 2023, [www.epa.gov/newsreleases/biden-harris-  
129 administration-announces-2-million-environmental-justice-projects-0](http://www.epa.gov/newsreleases/biden-harris-administration-announces-2-million-environmental-justice-projects-0). Accessed 1  
130 Dec. 2023.
  - 131 10. Weinstein, Casey, and Stephanie Howse. Regards Clean Energy and Energy  
132 Justice. 21 Sept. 2021, [www.legislature.ohio.gov/legislation/134/hb429](http://www.legislature.ohio.gov/legislation/134/hb429). Accessed 1  
133 Dec. 2023.

- 134 11. U.S. Attorney's Office, Southern District of Ohio. "Southern District of Ohio | U.S.  
135 Attorney Parker Launches Environmental Justice Initiative." *United States Attorney's*  
136 *Office Southern District of Ohio*, US Department of Justice, 4 Oct. 2022,  
137 [www.justice.gov/usao-sdoh/pr/us-attorney-parker-launches-environmental-justice-](http://www.justice.gov/usao-sdoh/pr/us-attorney-parker-launches-environmental-justice-initiative)  
138 [initiative](http://www.justice.gov/usao-sdoh/pr/us-attorney-parker-launches-environmental-justice-initiative). Accessed 1 Dec. 2023.
- 139 12. AMA Policy: Environmental Contributors to Disease and Advocating for  
140 Environmental Justice D-135.997
- 141 13. AMA Policy: Racism as a Public Health Threat H-65.952
- 142 14. AMA Policy: 135.024MSS Environmental Health Equity in Federally Subsidized  
143 Housing
- 144 15. AMA Policy: Stewardship of the Environment H-135.973
- 145 16. AMA Policy: Environmental Health Programs H-135.969

146  
147

148 OSMA Policy:

149

150 **Policy 27 – 2022 – Recognition of Climate Change as a Threat to Ohio’s Health**

- 151 1. The OSMA encourages the development of policy to combat climate change and its health  
152 effects in Ohio and to mitigate the undesirable environmental conditions that damage Ohioans’  
153 health.
- 154 2. The OSMA encourages education of the broader Ohio medical community to the serious  
155 adverse health effects of climate change and local conditions of climate variation.

156

157 **Policy 09 – 2019 – Impact of Climate Change on Human Health**

- 158 1. That the Ohio State Medical Association supports efforts at the state level for expansion of  
159 renewable sources of energy.

160

1  
2  
3  
4  
5  
6  
7  
8

**OHIO STATE MEDICAL ASSOCIATION HOUSE OF DELEGATES**

**Resolution No. 4 – 2025**

**WITHDRAWN BY SPONSORS**

1 **OHIO STATE MEDICAL ASSOCIATION HOUSE OF DELEGATES**

2  
3 **Resolution No. 5 – 2025**

4  
5 **Introduced by:** OSMA District 3

6  
7 **Subject:** Limits on Numbers of Resolutions

8  
9 **Referred to:** Resolutions Committee No. 1

10  
11 -----  
12  
13 **WHEREAS**, resolutions are submitted for discussion and vote by our OSMA HOD  
14 each year so that new OSMA policy can be established to serve as guidance for members  
15 and staff during discussion of new legislation, regulations, and rules in the State of Ohio  
16 and actions by our OSMA; and

17  
18 **WHEREAS**, resolutions that restate current Ohio law or rules or current OSMA  
19 policy are not helpful and waste the time and energy of OSMA members, Resolution  
20 Committee members, and Delegates during discussion and debate before and during the  
21 OSMA Annual Meeting; and

22  
23 **WHEREAS**, our members have limited time to review resolutions due to the time  
24 requirements of medical practice; and

25  
26 **WHEREAS** the number of resolutions has grown to an unmanageable number in  
27 the past few years; and therefore be it

28  
29 **RESOLVED**, that our OSMA limit the number of resolutions that can be submitted  
30 by any District, Section, or Specialty Society to 5 for each Annual Meeting, and be it  
31 further

32  
33 **RESOLVED**, that any OSMA member who individually wants to submit a resolution  
34 for discussion at the OSMA HOD must have a cosponsor which is a District, Section, or  
35 Specialty Society and that resolution will count towards the total number allowed for that  
36 District, Section, or Specialty Society.

37  
38  
39 **Fiscal Note:** \$ 500 (Sponsor)  
40 \$ 500 (Staff)

41  
42



46 Physicians are expected to uphold the ethical norms of their profession,  
47 including fidelity to patients and respect for patient self-determination. Yet  
48 physicians are not defined solely by their profession. They are moral agents  
49 in their own right and, like their patients, are informed by and committed to  
50 diverse cultural, religious, and philosophical traditions and beliefs. For some  
51 physicians, their professional calling is imbued with their foundational  
52 beliefs as persons, and at times the expectation that physicians will put  
53 patients' needs and preferences first may be in tension with the need to  
54 sustain moral integrity and continuity across both personal and professional  
55 life.

56  
57 Preserving opportunity for physicians to act (or to refrain from acting) in  
58 accordance with the dictates of conscience in their professional practice is  
59 important for preserving the integrity of the medical profession as well as  
60 the integrity of the individual physician, on which patients and the public  
61 rely.

62  
63 Thus physicians should have considerable latitude to practice in accord with  
64 well-considered, deeply held beliefs that are central to their self-identities.

65  
66 Physicians' freedom to act according to conscience is not unlimited,  
67 however. Physicians are expected to provide care in emergencies, honor  
68 patients' informed decisions to refuse life-sustaining treatment, and respect  
69 basic civil liberties and not discriminate against individuals in deciding  
70 whether to enter into a professional relationship with a new patient.

71  
72 In other circumstances, physicians may be able to act (or refrain from  
73 acting) in accordance with the dictates of their conscience without violating  
74 their professional obligations. Several factors impinge on the decision to act  
75 according to conscience. Physicians have stronger obligations to patients  
76 with whom they have a patient-physician relationship, especially one of long  
77 standing; when there is imminent risk of foreseeable harm to the patient or  
78 delay in access to treatment would significantly adversely affect the  
79 patient's physical or emotional well-being; and when the patient is not  
80 reasonably able to access needed treatment from another qualified  
81 physician.

82  
83 In following conscience, physicians should:

84 (a) Thoughtfully consider whether and how significantly an action (or  
85 declining to act) will undermine the physician's personal integrity, create  
86 emotional or moral distress for the physician, or compromise the physician's  
87 ability to provide care for the individual and other patients.

88 (b) Before entering into a patient-physician relationship, make clear any  
89 specific interventions or services the physician cannot in good conscience  
90 provide because they are contrary to the physician's deeply held personal

91 beliefs, focusing on interventions or services a patient might otherwise  
92 reasonably expect the practice to offer.

93 (c) Take care that their actions do not discriminate against or unduly burden  
94 individual patients or populations of patients and do not adversely affect  
95 patient or public trust.

96 (d) Be mindful of the burden their actions may place on fellow professionals.

97 (e) Uphold standards of informed consent and inform the patient about all  
98 relevant options for treatment, including options to which the physician  
99 morally objects.

100 (f) In general, physicians should refer a patient to another physician or  
101 institution to provide treatment the physician declines to offer. When a  
102 deeply held, well-considered personal belief leads a physician also to  
103 decline to refer, the physician should offer impartial guidance to patients  
104 about how to inform themselves regarding access to desired services.

105 (g) Continue to provide other ongoing care for the patient or formally  
106 terminate the patient-physician relationship in keeping with ethics guidance.

107

108

109 **Fiscal Note:** \$ 500 (Sponsor)

110 \$ 500 (Staff)

111

112 **References:**

113

114 1. AMA Principles of Medical Ethics: I,II,IV,VI,VIII,IX



50           **WHEREAS**, in this age of social media, it should be relatively easy to set up members-  
51 only websites with lists of physicians and physician spouses who are running for elected offices,  
52 and

53  
54           **WHEREAS**, it may be necessary for publicity of candidates for federal office to be a  
55 function of AMPAC and not the AMA (due to tax implications, legal concerns, etc); and

56  
57           **WHEREAS**, AMPAC and/or our AMA leaders may also determine that certain physicians  
58 or physician spouses who are running for elected office, may not merit this recognition; and

59  
60           **WHEREAS**, AMPAC and/or our AMA leaders may also determine that certain words or  
61 actions of certain physicians or physician spouses who are running for elected office, should merit  
62 removal from such lists; and

63  
64           **WHEREAS**, given limited resources and bandwidth, it is likely that this proposal should be  
65 a collaborative effort between AMPAC and the Political Action Committees (PACs) of our state  
66 and specialty societies; and

67  
68           **WHEREAS**, such a “vetting process” would likely consume valuable time and resources,  
69 such that AMPAC and/or AMA should consider whether the benefit outweighs the cost of doing  
70 this; and therefore be it

71  
72           **RESOLVED**, that our Ohio State Medical Association (OSMA) and AMA study the  
73 feasibility and desirability of working together with AMPAC (and state medical society/specialty  
74 society PACs, as appropriate) to publicize AMA physician members and physician spouses  
75 running for state, federal, and local offices (on AMA and/or OSMA websites), to help enable  
76 physicians and trainees to donate money, to contribute volunteer time, and to provide social  
77 media support for their campaigns; with a report back at A-26; and be it further

78  
79           **RESOLVED**, that our OSMA and American Medical Association (AMA) encourage AMA  
80 sections and caucuses to consider establishing a policy or protocol to allow (by invitation) AMA  
81 members running for local, state or federal offices to briefly address those groups directly, either  
82 virtually or in-person; and be it further

83  
84           **RESOLVED**, that our OSMA and American Medical Association (AMA) collaborate with  
85 other interested organizations to facilitate opportunities for AMA physician-member and  
86 physician-spouse elected officials (at the local, state, and federal levels) to connect, exchange  
87 ideas, collaborate, and support each other to protect our patients and our practices; and be it  
88 further

89  
90           **RESOLVED**, that our OSMA forward this resolution to AMA-HOD at A-25.

91  
92   **Fiscal Note:**           \$ 500 (Sponsor)  
93                               \$ 500 (Staff)

94  
95   **References:**

- 96  
1. Presentation on “Overview of State Legislatures, Policy, and Politics” at 2025 AMA State  
Advocacy Summit; Carlsbad, CA. Fri 10 Jan 2025

2. Presentation on “A Conversation with State Legislators” at 2025 AMA State Advocacy Summit; Carlsbad, CA. Fri 10 Jan 2025
3. “Statutes at Large and Public Laws” at congress.gov: <https://www.congress.gov/public-laws/118th-congress>; accessed 1/11/25
4. AMPAC Candidate Workshop and Campaign School, at <https://www.ampaonline.org/political-education/candidate-workshop-and-campaign-school-application>; accessed 1/11/25

97  
98  
99  
100  
101

**AMA physician members and spouses in state legislatures (2024-2025, \*NOT\* a comprehensive list):**

Name	State	Position in State Legislature	AMA role
Megan Srinivas, MD	Iowa (IA)	State Representative (District 30)	Former AMA Delegate, Former RFS Member of Council on Medical Service
Iowa State House website: <a href="https://www.legis.iowa.gov/legislators/legislator?personID=33973&amp;ga=91">State Representative https://www.legis.iowa.gov/legislators/legislator?personID=33973&amp;ga=91</a>  Campaign website: <a href="https://www.megan4iowa.com/">Megan Srinivas for Iowa House District 30 https://www.megan4iowa.com/</a>			
George Hruza, MD	Missouri (MO)	State Representative (District 089)	AMA Alt Delegate (for Missouri, also former MSMA/state medical society president, former AAD/national specialty society president)
Missouri State House website: <a href="https://house.mo.gov/memberdetails.aspx?district=089&amp;year=2025&amp;code=R">https://house.mo.gov/memberdetails.aspx?district=089&amp;year=2025&amp;code=R</a>  Campaign website: <a href="https://hruzaformissouri.com/">George Hruza for State Representative https://hruzaformissouri.com/</a>			
Trinidad Tellez, MD	New Hampshire (NH)	State Representative (District 40)	Spouse = Travis Harker, MD (AMA Delegate for NH)
New Hampshire State House website: <a href="https://gc.nh.gov/house/members/member.aspx?pid=10820">The New Hampshire House of Representatives https://gc.nh.gov/house/members/member.aspx?pid=10820</a>  Facebook page (no website for campaign contributions): <a href="https://www.facebook.com/share/156VQXHwpH/?mibextid=wXlfr">https://www.facebook.com/share/156VQXHwpH/?mibextid=wXlfr</a>			

Deborah Ferguson	Arkansas (AS)	State Representative (District 63)	Spouse = Scott Ferguson, MD (AMA Board of Trustees member)
	Arkansas State House website: <a href="#">Representative Deborah Ferguson (D) - Arkansas State Legislature</a>		
	Facebook page (no website for campaign contributions): <a href="#">Deborah Ferguson for Arkansas   Facebook</a>		

102  
103  
104  
105  
106  
107

**RELEVANT AMA POLICY – G-640.025**

Encourage Physicians as Legislative Candidates G-640.025

**Topic:** Governance **Policy Subtopic:** Advocacy and Political Action  
**Meeting Type:** Annual **Year Last Modified:** 2024  
**Action:** Consolidated **Type:** Governance Policies  
**Council & Committees:** Council on Constitution and Bylaws **Additional Councils & Committees:** CLRPD

108  
109  
110  
111  
112  
113  
114  
115  
116  
117

1. Our American Medical Association will continue to identify, encourage, and support physicians to run as state and national legislative **candidates**.
2. Our AMA will not use AMA corporate treasury funds to engage in.

Policy Timeline

Res. 605, A-14 Consolidated with G-645.015: CCB/CLRPD Rep. 01, A-24







47 **Fiscal Note:** \$ 50,000 (Sponsor)  
48 \$ 50,000 (Staff)

49

50

51 **References:**

52

53 1. OSMA Policy 19- 2007 - State Medical Board Oversight

54



47  
48  
49  
50

\$ 50,000 (Staff)



47 **References:**

48

49 1. OSMA Policy 14-2012

50 2. OSMA Policy 31-2021



47  
48       **WHEREAS**, the *Journal of Urban Health* published an editorial in 2016 titled  
49 “Excessive Police Violence as a Public Health Issue” which calls for further data  
50 acquisition, analyses, and interventions for mitigation of police violence<sup>8</sup>; and

51  
52       **WHEREAS**, the *Journal of Racial and Ethnic Health Disparities* published an  
53 article in 2020 titled “Police Brutality and Mistrust in Medical Institutions” reporting that  
54 negative encounters with police correlates with increased mistrust in the medical  
55 community and worse population health outcomes<sup>9</sup>; and

56  
57       **WHEREAS**, in 2017, the *American Journal of Public Health* identified five  
58 pathways linking police brutality to poor health outcomes in the African American  
59 community – including fatal injuries that increase population-specific mortality rates and  
60 adverse physiological responses that increase morbidity<sup>10</sup>; and

61  
62       **WHEREAS**, in 2023, the *American Journal of Public Health* reported increased  
63 rates of adverse health conditions for people living in heavily policed communities<sup>11</sup>; and

64  
65       **WHEREAS**, in 2018, the American Public Health Association passed the policy  
66 “Addressing Law Enforcement Violence as a Public Health Issue”<sup>12</sup>; and

67  
68       **WHEREAS**, in 2020, the American Medical Association (AMA) president published  
69 a statement entitled “Police brutality must stop” that states “AMA policy recognizes that  
70 physical or verbal violence between law enforcement officers and the public, particularly  
71 among Black and Brown communities where these incidents are more prevalent and  
72 pervasive, is a critical determinant of health and supports research into the public health  
73 consequences of these violent interactions”<sup>13</sup>; and

74  
75       **WHEREAS**, the AMA advocates for “research to be conducted that examines the  
76 public health consequences of negative interactions with police, including the impact on  
77 civilians and law enforcement professionals” (AMA Policy D-65.987)<sup>14</sup>; and

78  
79       **WHEREAS**, the AMA “recognizes police brutality as a manifestation of structural  
80 racism which disproportionately impacts Black, Indigenous, and other people of color”  
81 (AMA Policy H-65.954)<sup>15</sup>; and

82  
83       **WHEREAS**, the OSMA “supports actions that enable accurate reporting and data  
84 acquisition to target efforts to address the issue of arrest- and custody-related deaths”  
85 (OSMA Policy 24 – 2021 – Acknowledging Death in Custody in the State of Ohio as a  
86 Public Health Crisis)<sup>16</sup>; and therefore be it

87  
88       **RESOLVED**, that our Ohio State Medical Association recognizes police violence  
89 as a determinant of health due to its demonstrated adverse impact on population health  
90 and health disparities; and be it further

91

92           **RESOLVED**, that our Ohio State Medical Association supports the development  
93 and implementation of protocols for healthcare providers to identify, document, and report  
94 suspected cases of police brutality and violence.

95  
96 **Fiscal Note:**           \$ 500 (Sponsor)  
97                               \$ 500+ (Staff)

98  
99  
100 **References:**

- 101 1. Law Enforcement Epidemiology Project. School of Public Health. Accessed January  
102 15, 2024. <https://policeepi.uic.edu/>.
- 103 2. Justice Department announces closing of Investigation Into 2014 officer involved  
104 shooting in Cleveland, Ohio. Office of Public Affairs. December 29, 2020. Accessed  
105 January 15, 2024. [https://www.justice.gov/opa/pr/justice-department-announces-](https://www.justice.gov/opa/pr/justice-department-announces-closing-investigation-2014-officer-involved-shooting-cleveland)  
106 [closing-investigation-2014-officer-involved-shooting-cleveland](https://www.justice.gov/opa/pr/justice-department-announces-closing-investigation-2014-officer-involved-shooting-cleveland).
- 107 3. Laird J. Federal jury sides with Columbus officer in Tyre King's death. *The Columbus*  
108 *Dispatch*. [https://www.dispatch.com/story/news/courts/2023/01/26/federal-jury-](https://www.dispatch.com/story/news/courts/2023/01/26/federal-jury-acquits-columbus-cop-who-fatally-shot-13-year-old-in-2016/69843228007/)  
109 [acquits-columbus-cop-who-fatally-shot-13-year-old-in-2016/69843228007/](https://www.dispatch.com/story/news/courts/2023/01/26/federal-jury-acquits-columbus-cop-who-fatally-shot-13-year-old-in-2016/69843228007/).  
110 Published January 27, 2023.
- 111 4. The Official Mapping Police Violence Database. Mapping Police Violence. Accessed:  
112 31 December 2024. <https://mappingpoliceviolence.us/>.
- 113 5. CampaignZero. *Police Scorecard: Ohio Statewide, Nationwide Police Scorecard*.  
114 Accessed: 30 December 2024. <https://policesscorecard.org/oh>.
- 115 6. Hutchinson B. Third of officers in an Ohio police department hit with civil rights and  
116 abuse charges. *abcnews.go*. 2023. [https://abcnews.go.com/US/officers-ohio-police-](https://abcnews.go.com/US/officers-ohio-police-department-hit-civil-rights-abuse/story?id=97738257)  
117 [department-hit-civil-rights-abuse/story?id=97738257](https://abcnews.go.com/US/officers-ohio-police-department-hit-civil-rights-abuse/story?id=97738257).
- 118 7. More than half of police killings in USA are unreported and Black Americans are most  
119 likely to experience fatal police violence. Institute for Health Metrics and Evaluation.  
120 Accessed January 15, 2024. [https://www.healthdata.org/news-](https://www.healthdata.org/news-events/newsroom/news-releases/lancet-more-half-police-killings-usa-are-unreported-and-black)  
121 [events/newsroom/news-releases/lancet-more-half-police-killings-usa-are-](https://www.healthdata.org/news-events/newsroom/news-releases/lancet-more-half-police-killings-usa-are-unreported-and-black)  
122 [unreported-and-black](https://www.healthdata.org/news-events/newsroom/news-releases/lancet-more-half-police-killings-usa-are-unreported-and-black).
- 123 8. Cooper HL, Fullilove M. Editorial: Excessive Police Violence as a Public Health  
124 Issue. *J Urban Health*. 2016;93 Suppl 1(Suppl 1):1-7. doi:10.1007/s11524-016-0040-  
125 2.
- 126 9. Alang S, McAlpine DD, Hardeman R. Police Brutality and Mistrust in Medical  
127 Institutions. *J Racial Ethn Health Disparities*. 2020;7(4):760-768. doi:10.1007/s40615-  
128 020-00706-w
- 129 10. Alang S, McAlpine D, McCreedy E, Hardeman R. Police Brutality and Black Health:  
130 Setting the Agenda for Public Health Scholars. *Am J Public Health*. 2017;107(5):662-  
131 665. doi:10.2105/AJPH.2017.303691
- 132 11. Maren M. Spolum, William D. Lopez, Daphne C. Watkins, and Paul J. Fleming, 2023.  
133 Police Violence: Reducing the Harms of Policing Through Public Health-Informed  
134 Alternative Response Programs. American Journal of Public Health  
135 Health 113, S37\_S42, <https://doi.org/10.2105/AJPH.2022.307107>
- 136 12. Addressing law enforcement violence as a public health issue. Policy Statement  
137 Database. November 13, 2018. Accessed January 15, 2024.

- 138 [https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-](https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2019/01/29/law-enforcement-violence)  
139 [database/2019/01/29/law-enforcement-violence.](https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2019/01/29/law-enforcement-violence)
- 140 13. Ehrenfeld JM, Harris P. Police brutality must stop. [ama-assn.org](http://ama-assn.org). May 29, 2020.  
141 Accessed January 15, 2024. [https://www.ama-assn.org/about/leadership/police-](https://www.ama-assn.org/about/leadership/police-brutality-must-stop)  
142 [brutality-must-stop.](https://www.ama-assn.org/about/leadership/police-brutality-must-stop)
- 143 14. Policing Reform D-65.987. AMA Policy Finder. 2023. Accessed January 15, 2024.  
144 [https://policysearch.ama-](https://policysearch.ama-assn.org/policyfinder/detail/police%20reform?uri=%2FAMADoc%2Fdirectives.xml-D-65.987.xml)  
145 [assn.org/policyfinder/detail/police%20reform?uri=%2FAMADoc%2Fdirectives.xml-D-](https://policysearch.ama-assn.org/policyfinder/detail/police%20reform?uri=%2FAMADoc%2Fdirectives.xml-D-65.987.xml)  
146 [65.987.xml.](https://policysearch.ama-assn.org/policyfinder/detail/police%20reform?uri=%2FAMADoc%2Fdirectives.xml-D-65.987.xml)
- 147 15. Policing Reform H-65.954. AMA Policy Finder. 2023. Accessed January 15, 2024.  
148 [https://policysearch.ama-](https://policysearch.ama-assn.org/policyfinder/detail/police?uri=%2FAMADoc%2FHOD.xml-H-65.954.xml)  
149 [assn.org/policyfinder/detail/police?uri=%2FAMADoc%2FHOD.xml-H-65.954.xml.](https://policysearch.ama-assn.org/policyfinder/detail/police?uri=%2FAMADoc%2FHOD.xml-H-65.954.xml)
- 150 16. Acknowledging Death in Custody as a Public Health Crisis. OSMA Policy  
151 Compendium. 2021. Accessed January 15, 2024.  
152 [https://www.osma.org/aws/OSMA/pt/sp/policy-compendium.](https://www.osma.org/aws/OSMA/pt/sp/policy-compendium)

## **Relevant APHA, AMA, and OSMA Policy:**

### **American Public Health Association**

#### **Policy Number 201811 - Addressing Law Enforcement Violence as a Public Health Issue**

“APHA recommends the following actions by federal, state, tribal, and local authorities: (1) eliminate policies and practices that facilitate disproportionate violence against specific populations (including laws criminalizing these populations), (2) institute robust law enforcement accountability measures, (3) increase investment in promoting racial and economic equity to address social determinants of health, (4) implement community-based alternatives to addressing harms and preventing trauma, and (5) work with public health officials to comprehensively document law enforcement contact, violence, and injuries.”

### **American Medical Association**

#### **Policy D-65.987 - Policing Reform**

“Our AMA: (1) will advocate for efforts to implement evidence-based policing and the creation of evidence-based standards for law enforcement; (2) will advocate for sentinel event reviews in the criminal justice system following an adverse event, such as an in-custody death; (3) encourages further research by subject matter experts on the issues related to the transfer of military equipment to law enforcement agencies, including the impact on communities, particularly those in minoritized and marginalized communities; and (4) supports greater police accountability, procedurally just policing models, and greater community involvement in policing policies and practices. Our AMA advocates for (1) research to be conducted that examines the public health consequences of negative interactions with police, including the impact on civilians and law enforcement professionals; and (2) a change to the U.S. Standard Certificate of Death to include a “check box” that would capture deaths in custody and further

184 categorize the custodial death using cause and manner of death and information  
185 from the “How Injury occurred” section of the death certificate.”  
186

187 **Policy H-65.954 - Policing Reform**

188 “Our AMA: (1) recognizes police brutality as a manifestation of structural racism  
189 which disproportionately impacts Black, Indigenous, and other people of color; (2)  
190 will work with interested national, state, and local medical societies in a public  
191 health effort to support the elimination of excessive use of force by law  
192 enforcement officers; (3) will advocate against the utilization of racial and  
193 discriminatory profiling by law enforcement through appropriate anti-bias training,  
194 individual monitoring, and other measures; and (4) will advocate for legislation and  
195 regulations which promote trauma-informed, community-based safety practices.  
196 Our American Medical Association (1) recognizes the way we police our  
197 communities is a social determinant of health; (2) advocates for the reform of  
198 qualified immunity and other measures that shield law enforcement officers from  
199 consequences of misconduct to further address systemic racism in policing  
200 and mitigate use of excessive force; and (3) supports research on the impact upon  
201 employed physicians in law enforcement and the potential risk for exacerbating the  
202 physician workforce shortage within correctional medicine if qualified immunity  
203 was eliminated.”  
204

205 **Policy H-15.964 - Police Chases and Chase-Related Injuries**

206 “The AMA encourages (1) communities, aided by government officials and medical  
207 scientists, to develop and implement guidelines on the use of police vehicles that  
208 indicate when, how, and how long pursuits should be carried out and to address  
209 other key aspects of **police** pursuit; and (2) responsible government agencies to  
210 develop, test, and use instruments and techniques with advanced technologies,  
211 for example, coding and tracking devices, to discourage, eliminate, or replace high-  
212 speed chases.”  
213

214 **Ohio State Medical Association**

215 **Policy No. 24 – 2021 - Acknowledging Death in Custody in the State of Ohio**  
216 **as a Public Health Crisis**

217 “The OSMA supports actions that enable accurate reporting and data acquisition  
218 to target efforts to address the issue of arrest- and custody-related deaths.”  
219

220 **Emergency Policy No. 01 – 2018 - Firearms and Public Health**

221 “1. The OSMA opposes gun violence and supports policy that enforces patient  
222 safety. 2. The OSMA lobby for physician immunity from civil and criminal liability,  
223 if physicians are required to report potential violent threats by patients. 3. The  
224 OSMA encourages firearm safety education. Emergency Policy 01 – 2018 was  
225 reaffirmed at the 2019 OSMA House of Delegates.”  
226







47  
48 **WHEREAS**, initiatives promoting DEI increase enrollment of students  
49 underrepresented in medicine across marginalized communities, which helps create a  
50 workforce with more cultural humility that ensures the needs of all patients are met<sup>11</sup>; and  
51

52 **WHEREAS**, in March and April 2024, the Embracing anti-Discrimination, Unbiased  
53 Curricular, and Advancing Truth in Education (EDUCATE) Act was introduced in  
54 Congress, which sought to cut federal funding for U.S. medical schools with DEI  
55 programs, prompting opposition from various medical associations such as the AMA,  
56 AAMC, ACP, ACOG, AAEM, SAEM, and CHEST, among others<sup>12, 13, 14, 15, 16, 17, 18, 19</sup>; and  
57

58 **WHEREAS**, as of December 2024, 15 states have laws focused on restricting or  
59 banning DEI efforts in higher education, including medical education<sup>20, 21, 22</sup>; and  
60

61 **WHEREAS**, Ohio S.B. 83, known as the Enact Ohio Higher Education  
62 Enhancement Act, was originally introduced in 2023 and sought to ban mandatory DEI  
63 training unless required to comply with state and federal law, professional licensure  
64 requirements, or receiving accreditation or grants before it died in session at the end of  
65 2024<sup>23</sup>; and therefore be it  
66

67 **RESOLVED**, that our OSMA recognizes the integral role diversity, equity, and  
68 inclusion (DEI) play in developing culturally competent physicians and protecting the  
69 health of our patients; and be it further  
70

71 **RESOLVED**, that our OSMA oppose any effort to ban diversity, equity, or inclusion  
72 (DEI) in Ohio medical schools, especially any efforts to restrict state or federal funding for  
73 these schools based upon their promotion of DEI.  
74

75  
76 **Fiscal Note:**           \$ 500 (Sponsor)  
77                               \$ 500 (Staff)  
78

79 **References:**  
80

- 81 1. Diversity in Medical School Admissions. AAMC. Accessed December 9, 2024.  
82 [https://www.aamc.org/about-us/mission-areas/medical-education/diversity-](https://www.aamc.org/about-us/mission-areas/medical-education/diversity-medical-school-admissions)  
83 [medical-school-admissions](https://www.aamc.org/about-us/mission-areas/medical-education/diversity-medical-school-admissions)
- 84 2. Importance of Diversity in Health Care. AAMC. Accessed December 9, 2024.  
85 [https://www.aamc.org/about-us/mission-areas/medical-education/my-story-](https://www.aamc.org/about-us/mission-areas/medical-education/my-story-matters)  
86 [matters](https://www.aamc.org/about-us/mission-areas/medical-education/my-story-matters)
- 87 3. University of Cincinnati College of Medicine | Office of Diversity and Inclusion.  
88 Accessed December 9, 2024. <https://med.uc.edu/pathwayInnovation/home>
- 89 4. Office of Diversity and Inclusion. The Ohio State University College of Medicine.  
90 Accessed December 9, 2024. <https://medicine.osu.edu/diversity>
- 91 5. Equity, Diversity, & Inclusion. AAMC. Accessed December 9, 2024.  
92 <https://www.aamc.org/about-us/equity-diversity-inclusion>

- 93 6. Fact Sheet: The Need for Diversity in the Health Care Workforce. Health  
94 Professionals for Diversity Coalition. Accessed December 9, 2024.  
95 [https://www.aapcho.org/wp/wp-](https://www.aapcho.org/wp/wp-content/uploads/2012/11/NeedForDiversityHealthCareWorkforce.pdf)  
96 [content/uploads/2012/11/NeedForDiversityHealthCareWorkforce.pdf](https://www.aapcho.org/wp/wp-content/uploads/2012/11/NeedForDiversityHealthCareWorkforce.pdf)
- 97 7. Snyder JE, Upton RD, Hassett TC, Lee H, Nouri Z, Dill M. Black Representation  
98 in the Primary Care Physician Workforce and Its Association With Population Life  
99 Expectancy and Mortality Rates in the US. *JAMA Network Open*.  
100 2023;6(4):e236687. doi:10.1001/jamanetworkopen.2023.6687
- 101 8. Ma A, Sanchez A, Ma M. The Impact of Patient-Provider Race/Ethnicity  
102 Concordance on Provider Visits: Updated Evidence from the Medical Expenditure  
103 Panel Survey. *J Racial Ethn Health Disparities*. 2019;6(5):1011-1020.  
104 doi:10.1007/s40615-019-00602-y
- 105 9. Takeshita J, Wang S, Loren AW, et al. Association of Racial/Ethnic and Gender  
106 Concordance Between Patients and Physicians With Patient Experience Ratings.  
107 *JAMA Network Open*. 2020;3(11):e2024583.  
108 doi:10.1001/jamanetworkopen.2020.24583
- 109 10. Turner J, Higgins R, Childs E. Microaggression and Implicit Bias. *Am Surg*.  
110 2021;87(11):1727-1731. doi:10.1177/00031348211023418
- 111 11. Recognizing diversity's benefits in classrooms—and exam rooms. American  
112 Medical Association. October 31, 2022. Accessed December 9, 2024.  
113 [https://www.ama-assn.org/about/leadership/recognizing-diversity-s-benefits-](https://www.ama-assn.org/about/leadership/recognizing-diversity-s-benefits-classrooms-and-exam-rooms)  
114 [classrooms-and-exam-rooms](https://www.ama-assn.org/about/leadership/recognizing-diversity-s-benefits-classrooms-and-exam-rooms)
- 115 12. Sen. Kennedy J R L. Text - S.4115 - 118th Congress (2023-2024): EDUCATE  
116 Act. April 11, 2024. Accessed December 9, 2024.  
117 <https://www.congress.gov/bill/118th-congress/senate-bill/4115/text>
- 118 13. EDUCATE Act Introduced by Rep. Greg Murphy, M.D. AAMC. Accessed  
119 December 9, 2024. [https://www.aamc.org/advocacy-policy/washington-](https://www.aamc.org/advocacy-policy/washington-highlights/educate-act-introduced-rep-greg-murphy-md)  
120 [highlights/educate-act-introduced-rep-greg-murphy-md](https://www.aamc.org/advocacy-policy/washington-highlights/educate-act-introduced-rep-greg-murphy-md)
- 121 14. Statement on improving health through DEI. American Medical Association.  
122 March 26, 2024. Accessed January 17, 2025. [https://www.ama-assn.org/press-](https://www.ama-assn.org/press-center/press-releases/statement-improving-health-through-dei)  
123 [center/press-releases/statement-improving-health-through-dei](https://www.ama-assn.org/press-center/press-releases/statement-improving-health-through-dei)
- 124 15. ACOG Opposes Legislative Efforts to Erode Diversity, Equity, and Inclusion  
125 Initiatives in Medical Training. Accessed January 17, 2025.  
126 [https://www.acog.org/news/news-releases/2024/04/acog-opposes-legislative-](https://www.acog.org/news/news-releases/2024/04/acog-opposes-legislative-efforts-to-erode-diversity-equity-and-inclusion-initiatives-in-medical-training)  
127 [efforts-to-erode-diversity-equity-and-inclusion-initiatives-in-medical-training](https://www.acog.org/news/news-releases/2024/04/acog-opposes-legislative-efforts-to-erode-diversity-equity-and-inclusion-initiatives-in-medical-training)
- 128 16. ACP Addresses Legislation Aimed at Banning DEI Programs in Medical School.  
129 ACP Online. April 18, 2024. Accessed December 9, 2024.  
130 [https://www.acponline.org/advocacy/acp-advocate/archive/april-19-2024/acp-](https://www.acponline.org/advocacy/acp-advocate/archive/april-19-2024/acp-addresses-legislation-aimed-at-banning-dei-programs-in-medical-schools)  
131 [addresses-legislation-aimed-at-banning-dei-programs-in-medical-schools](https://www.acponline.org/advocacy/acp-advocate/archive/april-19-2024/acp-addresses-legislation-aimed-at-banning-dei-programs-in-medical-schools)
- 132 17. AAEM & AAEM/RSA Oppose the EDUCATE Act - AAEM. Accessed January 17,  
133 2025. <https://www.aaem.org/news/oppose-educate-act/>
- 134 18. Statement Opposing the EDUCATE Act | SAEM. Default. Accessed January 17,  
135 2025. [https://www.saem.org/about-saem/saem-strategic-plan/position-](https://www.saem.org/about-saem/saem-strategic-plan/position-statements/statement-opposing-the-educate-act)  
136 [statements/statement-opposing-the-educate-act](https://www.saem.org/about-saem/saem-strategic-plan/position-statements/statement-opposing-the-educate-act)
- 137 19. Expressing Support for DEI Within Medical Education - American College of Chest  
138 Physicians. Accessed January 17, 2025.

- 139 [https://www.chestnet.org/newsroom/chest-news/2024/04/expressing-support-](https://www.chestnet.org/newsroom/chest-news/2024/04/expressing-support-for-dei-within-medical-education)  
140 [for-dei-within-medical-education](https://www.chestnet.org/newsroom/chest-news/2024/04/expressing-support-for-dei-within-medical-education)
- 141 20. A Map of Anti-DEI Efforts on College Campuses Across the U.S. - EdTrust.  
142 Accessed December 9, 2024. [https://edtrust.org/rti/a-map-of-anti-dei-efforts-on-](https://edtrust.org/rti/a-map-of-anti-dei-efforts-on-college-campuses-across-the-u-s/)  
143 [college-campuses-across-the-u-s/](https://edtrust.org/rti/a-map-of-anti-dei-efforts-on-college-campuses-across-the-u-s/)
- 144 21. Attacks on DEI threaten med schools' efforts to recruit more Black students :  
145 Shots - Health News: NPR. Accessed December 9, 2024.  
146 [https://www.npr.org/sections/shots-health-news/2024/07/02/nx-s1-](https://www.npr.org/sections/shots-health-news/2024/07/02/nx-s1-5025660/medical-schools-recruit-black-students-dei-doctors)  
147 [5025660/medical-schools-recruit-black-students-dei-doctors](https://www.npr.org/sections/shots-health-news/2024/07/02/nx-s1-5025660/medical-schools-recruit-black-students-dei-doctors)
- 148 22. Bossi A. House Republicans are trying to upend DEI in medical schools. Prism.  
149 April 8, 2024. Accessed December 9, 2024.  
150 <http://prismreports.org/2024/04/08/dei-medical-schools/>
- 151 23. Senate Bill 83 | 135th General Assembly | Ohio Legislature. Accessed December  
152 9, 2024. <https://www.legislature.ohio.gov/legislation/135/sb83>

## 153 **RELEVANT OSMA POLICY**

### 154 **Policy 35-2021 – Integrating Anti-Racism Training in Medical School and graduate** 155 **medical education curricula and admissions**

- 156
- 157 1. The OSMA recognizes the benefit of anti-racism training in medical school and  
158 graduate medical education program curricula and admissions processes in  
159 increasing diversity of the medical field.
  - 160 2. The OSMA recommends all Ohio medical schools and graduate medical education  
161 programs utilize credible resources to implement recurrent, interactive (in-person  
162 or virtual) anti-racism training for medical students and graduate medical trainees  
163 and for all admission/selection committee members.

### 164 **Policy 36-2021 – LGBTQ Health and Medical Education in Ohio**

- 165 1. The OSMA recognizes the unique health care needs of our LGBTQ patients, and  
166 encourages LGBTQ-specific health education in both medical school and graduate  
167 medical education curricula.

### 168 **Policy 05 – 2019 – Advancing Gender Equity in Medicine**

- 169 1. The OSMA adopts the following, which is adapted from American Medical  
170 Association policy/directives:
  - 171 a. That the OSMA supports gender and pay equity in medicine consistent with  
172 the American Medical Association Principles for Advancing Gender Equity  
173 in Medicine (see below AMA Policy H-65.961 as adopted at the 2019 AMA  
174 Annual Meeting);
  - 175 b. That the OSMA: (a) Promote institutional, departmental, and practice  
176 policies, consistent with federal and Ohio law, that offer transparent criteria  
177 for initial and subsequent physician compensation; (b) Continue to advocate  
178 for pay structures based on objective, gender-neutral criteria; (c)  
179 Encourages training to identify and mitigate implicit bias in compensation  
180 decision making for those in positions to determine physician salary and  
181 bonuses, with a focus on how subtle differences in the further evaluation of  
182 physicians of different genders may impede compensation and career  
183 advancement;
  - 184 c. That the OSMA recommends as immediate actions to reduce gender bias

185 to: (a) Inform physicians about their rights under the Lilly Ledbetter Fair Pay  
186 Act, which restores protection against pay discrimination; (b) Promote  
187 educational programs to help empower physicians of all genders to  
188 negotiate equitable compensation; and (c) Work with relevant stakeholders  
189 to advance women in medicine;

190 d. That the OSMA collaborate with the American Medical Association  
191 initiatives to advance gender and pay equity;

192 e. That the OSMA commit to the principles of pay equity across the  
193 organization and take steps aligned with this commitment.

194 **Policy 06 – 2019 – Increase Awareness of Disparities in Medical Access and**  
195 **Treatment in Ohio**

- 196 1. The OSMA shall work with appropriate stakeholders to increase awareness of  
197 Ohio physicians, residents, and medical students of disparities in medical access  
198 and treatment in Ohio based on disability, race, ethnicity, geography, and other  
199 social and demographic factors through the utilization of existing resources.  
200

201 **RELEVANT AMA AND AMA-MSS POLICY**

202  
203 **Continued Support for Diversity in Medical Education D-295.963**

- 204 1. Our American Medical Association will publicly state and reaffirm its support for  
205 diversity in medical education and acknowledge the incorporation of DEI efforts as  
206 a vital aspect of medical training.
- 207 2. Our AMA will request that the Liaison Committee on Medical Education regularly  
208 share statistics related to compliance with accreditation standards IS-16 and MS-  
209 8 with medical schools and with other stakeholder groups.
- 210 3. Our AMA will work with appropriate stakeholders to commission and enact the  
211 recommendations of a forward-looking, cross-continuum, external study of 21st  
212 century medical education focused on reimagining the future of health equity and  
213 racial justice in medical education, improving the diversity of the health workforce,  
214 and ameliorating inequitable outcomes among minoritized and marginalized  
215 patient populations.
- 216 4. Our AMA will advocate for funding to support the creation and sustainability of  
217 Historically Black College and University (HBCU), Hispanic-Serving Institution  
218 (HSI), and Tribal College and University (TCU) affiliated medical schools and  
219 residency programs, with the goal of achieving a physician workforce that is  
220 proportional to the racial, ethnic, and gender composition of the United States  
221 population.
- 222 5. Our AMA will directly oppose any local, state, or federal actions that aim to limit  
223 diversity, equity, and inclusion initiatives, curriculum requirements, or funding in  
224 medical education.
- 225 6. Our AMA will advocate for resources to establish and maintain DEI offices at  
226 medical schools that are staff-managed and student- and physician-guided as well  
227 as committed to longitudinal community engagement.
- 228 7. Our AMA will investigate the impacts of state legislation regarding DEI-related  
229 efforts on the education and careers of students, trainees, and faculty.
- 230 8. Our AMA will recognize the disproportionate efforts by and additional

231 responsibilities placed on minoritized individuals to engage in diversity, equity, and  
232 inclusion efforts.

- 233 9. Our AMA will collaborate with the Association of American Medical Colleges, the  
234 Liaison Committee on Medical Education, and relevant stakeholders to encourage  
235 academic institutions to utilize Diversity, Equity, and Inclusion activities and  
236 community engagement as criteria for faculty and staff promotion and tenure.

237 **Model Legislation to Protect the Future of Medicine D-295.301**

238  
239 Our American Medical Association will create model state legislation to protect the ability  
240 of medical schools and residency/fellowship training programs to have diversity, equity,  
241 and inclusion (DEI) and related initiatives for their students, employees, and faculty to  
242 ensure the education and implementation of optimized healthcare.

243  
244 **Racial and Ethnic Disparities in Health Care H-350.974**

- 245 1. Our American Medical Association recognizes racial and ethnic health disparities  
246 as a major public health problem in the United States and as a barrier to effective  
247 medical diagnosis and treatment. The AMA maintains a position of zero tolerance  
248 toward racially or culturally based disparities in care; encourages individuals to  
249 report physicians to local medical societies where racial or ethnic discrimination is  
250 suspected; and will continue to support physician cultural awareness initiatives and  
251 related consumer education activities. The elimination of racial and ethnic  
252 disparities in health care an issue of highest priority for the American Medical  
253 Association.

- 254 2. Our AMA emphasizes three approaches that it believes should be given high  
255 priority:

256 1. Greater access - the need for ensuring that black Americans without  
257 adequate health care insurance are given the means for access to  
258 necessary health care. In particular, it is urgent that Congress address the  
259 need for Medicaid reform.

260 2. Greater awareness - racial disparities may be occurring despite the lack of  
261 any intent or purposeful efforts to treat patients differently on the basis of  
262 race. The AMA encourages physicians to examine their own practices to  
263 ensure that inappropriate considerations do not affect their clinical  
264 judgment. In addition, the profession should help increase the awareness  
265 of its members of racial disparities in medical treatment decisions by  
266 engaging in open and broad discussions about the issue. Such discussions  
267 should take place in medical school curriculum, in medical journals, at  
268 professional conferences, and as part of professional peer review activities.

269 3. Practice parameters - the racial disparities in access to treatment indicate  
270 that inappropriate considerations may enter the decision making process.  
271 The efforts of the specialty societies, with the coordination and assistance  
272 of our AMA, to develop practice parameters, should include criteria that  
273 would preclude or diminish racial disparities

- 274 3. Our AMA encourages the development of evidence-based performance measures  
275 that adequately identify socioeconomic and racial/ethnic disparities in quality.  
276 Furthermore, our AMA supports the use of evidence-based guidelines to promote

277 the consistency and equity of care for all persons.

278 4. Our AMA

- 279 1. actively supports the development and implementation of training regarding  
280 implicit bias, diversity and inclusion in all medical schools and residency  
281 programs.
- 282 2. will identify and publicize effective strategies for educating residents in all  
283 specialties about disparities in their fields related to race, ethnicity, and all  
284 populations at increased risk, with particular regard to access to care and  
285 health outcomes, as well as effective strategies for educating residents  
286 about managing the implicit biases of patients and their caregivers.
- 287 3. supports research to identify the most effective strategies for educating  
288 physicians on how to eliminate disparities in health outcomes in all at-risk  
289 populations.



46           **WHEREAS**, gender identity, transgender people, and intersex people continue to  
47 be threatened in the State of Ohio; and  
48

49           **WHEREAS**, our OSMA supports the protection of Lesbian, Gay, Transgender,  
50 Queer, Intersex, Asexual (LGBTQIA+) individuals from discriminating practices and  
51 harassment (Policy 22-2016) in addition to providing individualized, gender-affirming  
52 treatment and care (Policy 15-2020); and  
53

54           **WHEREAS**, the AMA supports an individual’s right to determine their gender  
55 identity on government documents and supports policies that allow for a gender change  
56 on said documents (H-65.967); and therefore be it  
57

58           **RESOLVED**, that the Ohio State Medical Association supports every individual’s  
59 right to determine their gender identity and sex designation on state-issued government  
60 documents including driver’s licenses; and be it further  
61

62           **RESOLVED**, that the Ohio State Medical Association supports policies that allow  
63 for a sex designation or change of designation on all state-issued government  
64 documentation to reflect an individual’s gender identity, as reported by the individual and  
65 without need for verification by a medical professional; and be it further  
66

67           **RESOLVED**, that the Ohio State Medical Association supports policies that include  
68 an undesignated or nonbinary gender option for state government records and forms of  
69 state government-issued identification.  
70

71  
72 **Fiscal Note:**           \$ 50,000 (Sponsor)  
73                               \$ 50,000 (Staff)  
74

75 **References:**

- 76       1. James, S.E., Herman, J.L., Durso, L.E., & Heng-Lehtinen, R. (2024). Early Insights: A Report  
77 of the 2022 U.S. Transgender Survey. National Center for Transgender Equality, Washington,  
78 DC.  
79       2. Scheim, A. I., Perez-Brumer, A. G., & Bauer, G. R. (2020). Gender-concordant identity  
80 documents and mental health among transgender adults in the USA: A cross-sectional study.  
81 The Lancet. Public Health, 5(4), e196–e203. [https://doi.org/10.1016/S2468-2667\(20\)30032-3](https://doi.org/10.1016/S2468-2667(20)30032-3)  
82       3. <https://dam.assets.ohio.gov/image/upload/publicsafety.ohio.gov/bmv2369.pdf>  
83       4. [https://www.wosu.org/politics-government/2024-12-11/ohio-county-probate-court-judges-](https://www.wosu.org/politics-government/2024-12-11/ohio-county-probate-court-judges-weigh-in-on-unequal-access-to-birth-certificate-changes)  
84 [weigh-in-on-unequal-access-to-birth-certificate-changes](https://www.wosu.org/politics-government/2024-12-11/ohio-county-probate-court-judges-weigh-in-on-unequal-access-to-birth-certificate-changes)  
85       5. <https://equalityohio.org/legal-clinic/trans-know-your-rights/>  
86       6. [http://www.lgbtmap.org/equality-maps/identity\\_document\\_laws](http://www.lgbtmap.org/equality-maps/identity_document_laws)  
87

88 **Relevant AMA Policy**

89 Conforming Sex and Gender Designation on Government IDs and Other Documents H-65.967

- 90       1. Our American Medical Association supports every individual’s right to determine  
91 their gender identity and sex designation on government documents and other  
92 forms of government identification.

- 93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107
2. Our AMA supports policies that allow for a sex designation or change of designation on all government IDs to reflect an individual's gender identity, as reported by the individual and without need for verification by a medical professional.
  3. Our AMA supports policies that include an undesignated or nonbinary gender option for government records and forms of government-issued identification, which would be in addition to "male" and "female."
  4. Our AMA supports efforts to ensure that the sex designation on an individual's government-issued documents and identification does not hinder access to medically appropriate care or other social services in accordance with that individual's needs.
  5. Our AMA will advocate for the removal of sex as a legal designation on the public portion of the birth certificate, recognizing that information on an individual's sex designation at birth will still be submitted through the U.S. Standard Certificate of Live Birth for medical, public health, and statistical use only.



47           **WHEREAS**, there is not a single long-term study to demonstrate the safety and  
48 efficacy of puberty blockers, cross-sex hormones, and surgery for restoring wellbeing in  
49 transgender believing youth. To paraphrase Hillary Cass, the former president of the  
50 Royal College of Pediatric and Child Health Services in England and author of the Cass  
51 Review, the scientific foundations for gender affirming care rest on “shaky ground” (9)  
52 (10) (11) (12); and

53  
54           **WHEREAS**, gender incongruence is neither innate nor immutable and 61-98% of  
55 incongruent identities have been documented to align with their biological sex across their  
56 lifespan, and usually by late adolescence, including with or without counseling (15) (16)  
57 (17) (18) (19); and

58  
59           **WHEREAS**, 43-75% of incongruent youth have a significant and untreated mental  
60 illness that pre-dated their symptoms of gender incongruence, and many supposed  
61 gender non-conforming teens may confuse their anxiety disorders, eating disorders,  
62 autism spectrum disorders, mood disorders or childhood trauma with gender dysphoria  
63 (20) (21) (22) (23); and

64  
65           **WHEREAS** the use of puberty blockers to suppress normally timed puberty is  
66 dangerous to youth as evidence points to such interventions being associated with  
67 mental illness and other serious health consequences, and over 90% of adolescents on  
68 blockers will go on to use cross-sex hormones (24) (25) (26) (27); and

69  
70           **WHEREAS**, the package-insert for Lupron, the number one prescribed puberty  
71 blocker in America lists “emotional instability” as a side effect and warns prescribers to  
72 “monitor for development or worsening of psychiatric symptoms during treatment”; and

73  
74           **WHEREAS**, temporary use of Lupron has been associated with and may be the  
75 cause of many serious permanent side effects including osteoporosis, mood disorders,  
76 seizures, cognitive impairment, voice change, and when combined with cross-sex  
77 hormones, sterility. In addition to the Lupron harm, cross-sex hormones bring youth  
78 increased risk of heart attacks, stroke, diabetes, blood clots and cancers across their  
79 lifespan (27) (28) (29) (30) (31) (32) (33) (51) (57); and

80  
81           **WHEREAS**, “gender affirming care” in youth frequently fails to achieve the goal of  
82 improving the life of the recipient, and the incidence of suicide is much higher in recipients  
83 of “gender affirming care” than in the non-treated transgender population (8) (10) (11)  
84 (15) (31) (34) (36); and

85  
86           **WHEREAS**, currently, girls as young as age 13 are receiving double  
87 mastectomies, and boys as young as 16 years of age are receiving breast implants and  
88 are being surgically castrated, undergoing penectomies and having pelvic wounds  
89 created to simulate female vaginas. No parent or guardian has any right to allow such  
90 mutilation (52) (53) (54) (58) (59) (60); and

91

92           **WHEREAS**, OSMA has already adopted Policy 07-2019 Female Genital Mutilation  
93 Ban which condemns the practice of female genital mutilation as defined by the World  
94 Health Organization and considers female genital mutilation a form of child abuse; and  
95

96           **WHEREAS**, youth transition can be considered experimental, bringing into  
97 question the ability of and the right of parents or guardians to provide informed consent,  
98 the propriety of providers to request and obtain informed consent, and of minors to assent  
99 to such medical or surgical treatments (13) (14) (49); and  
100

101           **WHEREAS**, many European nations have called a halt on gender affirming care  
102 in minors including Norway, Sweden, Finland, Belgium, the Netherlands, France and the  
103 United Kingdom (UK) unless in rigidly controlled circumstances such as in England,  
104 where treatment is part of a carefully crafted controlled multicenter study including  
105 thorough pre- and long term post-psychological evaluation and follow-up, designed to  
106 determine the harms vs benefits of such treatments (10) (37) (38) (39); and  
107

108           **WHEREAS**, there is appearing on the horizon some potential legal jeopardy for  
109 parents, guardians, providers and institutions from plaintiffs who feel that as transgender  
110 individuals their lives were permanently and cruelly altered in the name of “gender  
111 affirming care”. Organizations espousing such treatments could potentially also become  
112 targets of imaginative attorneys (40) (41) (42); and  
113

114           **WHEREAS**, the most truthful and compassionate approach toward children and  
115 adolescents questioning their gender is to allow them to be themselves without undue  
116 attention and pressure related to culturally determined gender roles, while providing  
117 adequate psychological care addressing mental and emotional health concerns; and  
118 therefore  
119

120           **BE IT RESOLVED**, that our OSMA rescind its prior policies 05-2023 & 15-2020  
121 which support gender-altering treatments; and be it further  
122

123           **RESOLVED**, that OSMA recommend to the AMA that the United States join with  
124 the nations of England, Scotland, Finland, Norway, Sweden, The Netherlands, Belgium,  
125 and France in calling a halt to all gender altering treatments in minors unless administered  
126 in rigidly controlled circumstances such as part of a tightly controlled long term study; and  
127 be it further  
128

129           **RESOLVED**, that OSMA recommend to any interested parties that a retrospective  
130 study be instituted for long-term follow up evaluation of all minors who have been subject  
131 to gender altering interventions; and be it further  
132

133           **RESOVLED**, that OSMA report to the Governor and the leaders of the Ohio House  
134 and Senate that OSMA supports the recent gender legislation (HB 68) that was passed  
135 into law; and be it further  
136

137           **RESOLVED**, that the term “gender affirmation” be replaced with “gender alteration”  
138 in all discussions regarding the attempt at changing a person’s sex to fit socially  
139 constructed roles; be it further  
140

141           **RESOLVED**, that our OSMA adopt as a standard policy recommendation that  
142 people struggling with gender dysphoria be allowed to develop free of external pressures  
143 while having mental, emotional, and spiritual support services that help them through their  
144 unique individual process of understanding who they are.  
145

146  
147 **Fiscal Note:**           \$ 500 (Sponsor)

148                               \$ 500+ (Staff)  
149

150 **References:**

- 151       1. Frew, T., et al Gender Dysphoria and Psychiatric Comorbidities in Childhood: a  
152       systematic review. *Australian Journal of Psychology*, 73 (3): 255-271
- 153       2. American Psychological Association, pamphlet: “Understanding Transgender  
154       People, Gender Identity, and Gender Expression”. last reviewed July 8, 2024
- 155       3. “Gender” Online Etymology Dictionary, [https:](https://www.etymonline.com/word/gender)  
156       [//www.etymonline.com/word/gender](https://www.etymonline.com/word/gender) (June 20, 2023)
- 157       4. Oakley, Ann, “Sex, Gender, and Society” (U.S. and UK: Routledge, 2015) This is  
158       a reprint of the original book, with an updated introduction.
- 159       5. Haig, David, *The Inexorable Rise of Gender and the Decline of Sex: Social*  
160       *Change in Academic Titles, 1945-2001*. *Archives of Social Behavior* 33: 87-96  
161       April 2004
- 162       6. “Gender Stereotyping” Office of the United Nations High Commissioner of  
163       Human Rights, 2023 <https://www.ohchr.org/en/women/gender-stereotyping>  
164       (August 2, 2023)
- 165       7. Fine, Cordelia, “Delusions of Gender: how our minds, society, and neurosexism  
166       create differences”. W.W. Norton & Company New York, 2010
- 167       8. Curtis, Carla, “The Gender Trap: the trans agenda’s war against children”.  
168       Introduction, pages xiv – xvi, *Gays Against Grooming Publishing, Bayliss*  
169       *Wisconsin, 2024*
- 170       9. Abbasi, Kamran, Editor in Chief, *British Medical Journal*, *The Cass Review: an*  
171       *opportunity to unite behind informed care in gender medicine*. *British Medical*  
172       *Journal* 385: 837-838 (editorial), April 11, 2024
- 173       10. Cass, Hillary, *Gender medicine in children and young people is built on shaky*  
174       *foundations, here is how we strengthen services*. *British Medical Journal* 385:  
175       814 (April 2024)
- 176       11. Cass, Hillary, *Independent review of gender identity services for children and*  
177       *young people Final report released in Spring 2024*. Available for download, 364  
178       pages
- 179       12. Hruz, P. W., *Deficiencies in scientific evidence for medical management in*  
180       *gender dysphoria*. *The Linacre Quarterly*, 87 (1): 34-42, 2024
- 181       13. Latham, A. (2022) *Puberty Blockers for children: can they consent?* *The New*  
182       *Bioethics* 28 (3): 268-291

- 183 14. Levine, Stephan B., Abbrozzese, E., (2023) Current concerns about gender  
184 aFirming therapy in adolescents. *Current Sexual Health Reports* 15: 113-123.
- 185 15. Drummond, K.D., Bradley, S. J., Peterson-Badali, M., and Zucker, K. J., (2008)  
186 A follow-up study of girls with gender identity disorder. *Developmental*  
187 *Psychology*, 44(1): 34-45
- 188 16. Ristori, J. Steensma, T.D., (2016) Gender Dysphoria in Childhood. *Int Rev*  
189 *Psychiatry* 28 (1): 13-20.
- 190 17. Singh, D., Bradley, S.J., et al, A follow-up study of boys with gender identity  
191 disorder. *Frontiers in Psychiatry*, 12,287.  
192 <https://doi.org/10.3389/fpsy.2021.632784>.
- 193 18. Green, R. (1987) The “sissy boy syndrome” and the development of  
194 homosexuality. Yale University Press
- 195 19. Wallien, M.S C., and Cohen-Kettenis, P.T. (2008) Psychosexual outcome of  
196 gender dysphoria children. *Journal of the American Academy of Child and*  
197 *Adolescent Psychiatry*, 47(12) 1413-1423.
- 198 20. Otero-Paz, M., et al, A 2020 review of mental health comorbidity in gender  
199 dysphoric and gender non-conforming people. *Journal of Psychiatric Treatment*  
200 *and Research* 3(1)
- 201 21. Litman, L. (2018) Rapid onset gender dysphoria in adolescents and young  
202 adults: A study of parental reports. *Plos One* 13(8): e0202330.[https://doi.org/](https://doi.org/10.1371/journal.pone.0202330)  
203 [10.1371/journal.pone.0202330](https://doi.org/10.1371/journal.pone.0202330)
- 204 22. Kaltiala-Heino, R., Sumia, M., Tyolajarvi, M., Lindberg, N., (2015) Two years of  
205 gender identity services for minors: overrepresentation of natal girls with severe  
206 problems in adolescent development. *Childhood and Adolescent Psychiatry and*  
207 *Mental Health* 90(9).
- 208 23. Heylens, G., et al, (2014) Psychiatric characteristics of transsexual individuals: a  
209 multicentre study in four European countries. *The British Journal of Psychiatry*  
210 204(2) 151-156.
- 211 24. National Institute for Health and Care Excellence (2020) Evidence review:  
212 gender aFirming hormones for children and adolescents with gender dysphoria.
- 213 25. Respaut, R., Terhune, C., (2022) “Putting numbers on the rise in children  
214 seeking gender care”. Reuters
- 215 26. Carmichael, P., et al, (2021) Short-term outcomes of pubertal suppression in a  
216 selected cohort of 12-15-year-old young people with persistent gender dysphoria  
217 in the UK. *Med Rxiv*. <https://doi.org/10.1106/2v020.12.0120241653>
- 218 27. Biggs, M., (2021) Revisiting the eMect of genRH analogue treatment on bone  
219 mineral density in young adolescents with gender dysphoria. *Journal of Pediatric*  
220 *Endocrinology and Metabolism* 34(7): 937-939
- 221 28. Baldassarre, M., et al, (2013) EMects of long-term high dose testosterone  
222 administration on vaginal epithelium structure and estrogen receptor-a and -b  
223 expression of young women. *International Journal of Impotence Research*, 25,  
224 172-177
- 225 29. Irving, A., Lehault, W., (2017) Clinical pearls of gender aFirming hormone  
226 therapy in transgender patients. *Mental Health Clinician*, 7 (4): 164-167

- 227 30. Alzahrani, Talal, et al, (2019), cardiovascular disease, risk factors and  
228 myocardial infarction in the transgender population. *Circulation: Cardiovascular*  
229 *Quality and Outcomes*, 12 (4), doi:10.461/circoutcomes.119.085597
- 230 31. Schmidt, L., Levine, R., (2015) Psychological outcomes and reproductive issues  
231 among gender dysphoric individuals. *Endocrinology Metabolism Clinics of North*  
232 *America*, 44, 773-785
- 233 32. Vlot, M.C., Klink, D., den Heijer, M., Wiepjes, C.M., Blankenstein, M.A., Rotteveel,  
234 J., Heijboer, A.C., (2017) Effect of pubertal suppression and cross-sex hormone  
235 therapy on bone turnover markers and bone mineral apparent density in  
236 transgender adolescents. *Bone*, 95, 11-19
- 237 33. Islam, N., et al (2021) Is there a link between hormone use and diabetes  
238 incidence in transgender people? Data from the Strong Cohort. *The Journal of*  
239 *Clinical Endocrinology and Metabolism*. <https://doi.org/10.1210/clinem/dgab832>
- 240 34. Asscheman, H., Giltay, E. J., et al, (2011) A long term follow-up of mortality in  
241 transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinology*.  
242 164(4): 635-42.
- 243 35. Kaltiala, R., et al (2019) Adolescent development and psychosocial functioning  
244 after starting cross-sex hormones for gender dysphoria. *Nordic Journal of*  
245 *Psychiatry*. DOI: 10.1080/08039480.2019.1691260
- 246 36. Wiepjes, C.M., den Heijer, M., Steensma, T.D., et al. (2021) Trends in suicide  
247 death risk in transgender people: results from the Amsterdam cohort of gender  
248 dysphoria study. (1972-2017). *Acta Psychiatr Scand*. 141: 486-491.
- 249 37. Patient Safety for children and young people with gender incongruence. (2023)  
250 Norwegian Healthcare Investigation Board.
- 251 38. Linden, T., (2022) Updated recommendations for hormone therapy for gender  
252 dysphoria in young people. National Board of Health and Welfare (Sweden)
- 253 39. Medical treatment methods for dysphoria related to gender variance in minors.  
254 (2020). Recommendation of the Council for Choices in Healthcare in Finland.  
255 (PALKO / COHERE Finland)
- 256 40. *Clementine Breen vs Johanna Olsen-Kennedy M.D., and Children's Hospital of*  
257 *Los Angeles and others in Superior Court of California in and for the County of*  
258 *Los Angeles*. According to the NY Times, defendant Dr Olson-Kennedy who  
259 was a pioneer in developing gender affirmation surgery and is founder and  
260 medical director of the Center for Transyouth Health and Development, is also  
261 being sued by a taxpayer group for withholding the results of a \$10 million  
262 taxpayer funded study showing that puberty blockers did not improve the mental  
263 health of recipients.
- 264 41. *Soren Aldace vs Dell Scott Perry et al, and Crane Clinic PLC and others in*  
265 *Tarrant County District Court of Texas*.
- 266 42. Stieber, Zachary, "Girl Sues Hospital for Removing Her Breasts at Age 13." *The*  
267 *Epoch Times*, June 15, 2023. The plaintiff here is also featured in  
268 "Detransitioner Chloe Cole's full testimony to Congress is a "final warning" to  
269 stop gender surgery". *New York Post*, August 9, 2023.
- 270 43. Biggs, M, (2020) Puberty Blockers and suicidality in adolescents suffering from  
271 gender dysphoria. *Archives of Sexual Behavior*, 49: 2227-2229

- 272 44. Chang, P.J, Pastuszak A.W., et al, Fertility concerns of the transgender patient.  
273 Translational Andrological Urology, 8(3): 209-218
- 274 45. Simonsen, R.K., Giraldi, A., et al, (2016) Long-term follow-up of individuals  
275 undergoing sex reassignment surgery: Psychiatric morbidity and mortality.  
276 Nordic Journal of Psychiatry, 70: 241-247
- 277 46. StoMers, I.E., de Vries, M.C., and Hannema, S.E., (2019) Physical changes,  
278 laboratory parameters, and bone mineral density during testosterone treatment  
279 in adolescents with gender dysphoria. The Journal of Sexual Medicine, 16(9):  
280 1459-1468
- 281 47. De Vries, A., Steensma, T.D., Doreleijers, T.A. et al, (2011) Puberty suppression  
282 in adolescents with gender identity disorder; a prospective follow-up study. The  
283 Journal of Sexual Medicine 8(8) 2276-2289
- 284 48. Wiepjes, C.M., Nota, C.M., Blok, C.J.W., et al, (2018) The Amsterdam cohort of  
285 gender dysphoria study (1972-2015): trends in prevalence, treatment, and  
286 regrets. Journal of Sexual Medicine, 15(4): 582-590
- 287 49. Levine, S., Abbruzzese, E., and Mason, J., (2022). Reconsidering informed  
288 consent for trans-identified children, adolescents, and young adults. Journal of  
289 Sex and Marital therapy, 48 (7): 706-727
- 290 50. Brik, T., Vrouwenraets, L.J., de Vries, M.C., and Hannema, S.E., (2020).  
291 Trajectories of adolescents treated with gonadotropin releasing hormone  
292 analogues for gender dysphoria. Archives of Sexual Behavior, 49(7): 2611-2618
- 293 51. Nota, N.M., Wiepjes, C.M., et al, (2019) Occurrence of acute cardiovascular  
294 events in transgender individuals receiving hormone therapy: results from a  
295 large cohort study. Circulation, 139 (11): 1461-1462
- 296 52. Natalie Stone, "Jazz Jennings Says She's "Doing Great" After Undergoing  
297 Gender AMirring Surgery", People Magazine, June 28, 2018,  
298 [https://people.com/tv/jazz-jennings-doing-grear-after-gender-confirmation-](https://people.com/tv/jazz-jennings-doing-grear-after-gender-confirmation-surgery-photo/)  
299 [surgery-photo/](https://people.com/tv/jazz-jennings-doing-grear-after-gender-confirmation-surgery-photo/).
- 300 53. Nina Strohlic, "In the Operating Room During Gender Reassignment Surgery",  
301 National Geographic, December 29, 2016,  
302 [https://www.nationalgeographic.com/news/2016/12/gender-confirmation-surgery-](https://www.nationalgeographic.com/news/2016/12/gender-confirmation-surgery-transition/)  
303 [transition/](https://www.nationalgeographic.com/news/2016/12/gender-confirmation-surgery-transition/)
- 304 54. "Transgender Kids: Who Knows Best". Directed by John Conroy. London: BBC  
305 Two, 2017. Retrieved from: <https://vimeo.com/217950594>
- 306 55. Richardson, Valerie, "Ex-transgender "detransitioners" raise red flags about  
307 gender-aMirring care". The Washington Times, March 14, 2023
- 308 56. Littman, Lisa, Individuals Treated for Gender Dysphoria with Medical and/or  
309 Surgery Who Subsequently Detransitioned: A Survey of 100 Detransitioners.  
310 Archives of Sexual Behavior, 2021 Number 50, 3353-3369.
- 311 57. Curtis, Carla, "The Gender Trap: the trans agenda's war against children", pages  
312 98-104, Gays Against Grooming Publishing, Bayliss Wisconsin, 2024
- 313 58. Curtis, Carla, "The Gender Trap: the trans agenda's war against children", pages  
314 105-108, Gays Against Grooming Publishing, Bayliss Wisconsin, 2024
- 315 59. "Understanding the Transgender Issue" Parents Resource Guide 2019  
316 published by Minnesota Family Council jointly with ROGO, WoLF, The Kelsey  
317 Foundation, The Heritage Foundation, and Family Council.

318  
319

60. American College of Pediatricians website



47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

**WHEREAS**, Rhode Island’s 2010 affordability standards imposed price controls by implementing inflation caps and diagnosis-based payments on contracts between commercial insurers and hospitals and clinics and required commercial insurers to increase their spending on primary care and care coordination services, which decreased quarterly fee-for-service spending by \$76 per enrollee, or a decrease of 8.1%, without changing quality measures between 2007-2016<sup>18</sup>; and

**WHEREAS**, Rhode Island now requires insurers to invest at least 10.7% of their total medical expenses in primary care<sup>19</sup>; and

**WHEREAS**, Delaware has a similar target of 11.5% of spending into primary care by 2025 while mandating insurers reimburse at least at Medicare rates<sup>20</sup>; and

**WHEREAS**, Colorado require insurers increase their primary care investment by 2% from 2021-2023 while prohibiting insurers from raising their premiums to offset the cost<sup>21</sup>; and

**WHEREAS**, OSMA has policies which necessitate knowing healthcare spending dollars, aim to make healthcare more affordable [Policy 18-2016, 18-2019, 18-2021, 20-2022, 27-2023, 6-2023], and promote primary care [Policy 30-1994, 8-2013]; and

**WHEREAS**, AMA policies advocate for expanding Medicaid eligibility and enhancing premium tax credits to cover uninsured populations, thereby addressing the affordability and accessibility gaps in the current healthcare system [Policy H-165.824]; and therefore be it

**RESOLVED**, that our OSMA advocates for statewide tracking of healthcare expenses and establish a maximum growth rate for total healthcare costs to curb rising expenses; and be it further

**RESOLVED**, that our OSMA advocate for inflation caps and diagnosis-based payments in contracts between insurers and providers to manage healthcare costs; and; and be it further

**RESOLVED**, that our OSMA advocates for state targets for commercial insurers to increase their total health expenses percentage in primary care and care coordination as a strategy to control healthcare spending.

**Fiscal Note:**           **\$50,000 (Sponsor)**  
                                  **\$50,000 (Staff)**

93 **References:**

- 94
- 95 1. *How does health spending in the U.S. compare to other countries? - Peterson-*
- 96 *KFF Health System Tracker.* (2024, January 23). Peterson-KFF Health System
- 97 Tracker. [https://www.healthsystemtracker.org/chart-collection/health-spending-u-](https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/#GDP%20per%20capita%20and%20health%20consumption%20spending%20per%20capita,%202022%20(U.S.%20dollars,%20PPP%20adjusted))
- 98 [s-compare-](https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/#GDP%20per%20capita%20and%20health%20consumption%20spending%20per%20capita,%202022%20(U.S.%20dollars,%20PPP%20adjusted))
- 99 [countries/#GDP%20per%20capita%20and%20health%20consumption%20spending%20per%20capita,%202022%20\(U.S.%20dollars,%20PPP%20adjusted\)](https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/#GDP%20per%20capita%20and%20health%20consumption%20spending%20per%20capita,%202022%20(U.S.%20dollars,%20PPP%20adjusted))
- 100
- 101 2. The Health Policy Institute of Ohio. (2024). *HEALTH DASHBOARD.*
- 102 <https://www.healthpolicyohio.org/files/assets/2024healthvaluedashboardfinal.pdf>
- 103 3. *National Health Expenditures 2022 Highlights | CMS.* (2024, June 12).
- 104 [https://www.cms.gov/newsroom/fact-sheets/national-health-expenditures-2022-](https://www.cms.gov/newsroom/fact-sheets/national-health-expenditures-2022-highlights)
- 105 [highlights](https://www.cms.gov/newsroom/fact-sheets/national-health-expenditures-2022-highlights)
- 106 4. Ani Turner, George Miller, and Elise Lowry, *High U.S. Health Care Spending: Where Is It All Going?* (Commonwealth Fund, Oct. 2023).
- 107 <https://doi.org/10.26099/r6j5-6e66>
- 108 5. *Health Care Costs and Affordability | KFF.* (2024, October 24). KFF.
- 109 [https://www.kff.org/health-policy-101-health-care-costs-and-](https://www.kff.org/health-policy-101-health-care-costs-and-affordability/?entry=table-of-contents-how-do-high-health-costs-affect-affordability-of-care)
- 110 [affordability/?entry=table-of-contents-how-do-high-health-costs-affect-](https://www.kff.org/health-policy-101-health-care-costs-and-affordability/?entry=table-of-contents-how-do-high-health-costs-affect-affordability-of-care)
- 111 [affordability-of-care](https://www.kff.org/health-policy-101-health-care-costs-and-affordability/?entry=table-of-contents-how-do-high-health-costs-affect-affordability-of-care)
- 112
- 113 6. Lopes, L., Montero, A., Presiado, M., & Hamel, L. (2024, May 7). *Americans’*
- 114 *Challenges with Health Care Costs | KFF.* KFF. [https://www.kff.org/health-](https://www.kff.org/health-costs/issue-brief/americans-challenges-with-health-care-costs/)
- 115 [costs/issue-brief/americans-challenges-with-health-care-costs/](https://www.kff.org/health-costs/issue-brief/americans-challenges-with-health-care-costs/)
- 116 7. *Health care debt in the U.S.: The Broad consequences of medical and dental*
- 117 *bills - Main findings - 9957 | KFF.* (2024, February 13). KFF.
- 118 <https://www.kff.org/report-section/kff-health-care-debt-survey-main-findings/>
- 119 8. Himmelstein DU, Dickman SL, McCormick D, Bor DH, Gaffney A, Woolhandler S. Prevalence and Risk Factors for Medical Debt and Subsequent Changes in Social Determinants of Health in the US. *JAMA Netw Open.* 2022;5(9):e2231898. doi:10.1001/jamanetworkopen.2022.31898
- 120
- 121 9. Health Expenditures by State of Residence, 1991-2020. National health expenditure data, Center for Medicare & Medicaid.
- 122
- 123 10. Rui P, Okeyode T. National Ambulatory Medical Care Survey: 2016 National Summary Tables. Accessed March 29, 2020,
- 124
- 125 [https://www.cdc.gov/nchs/data/ahcd/namcs\\_summary/2016\\_namcs\\_web\\_tables.](https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2016_namcs_web_tables.pdf)
- 126 [pdf](https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2016_namcs_web_tables.pdf)
- 127
- 128 11. Petterson SM, Liaw WR, Phillips RL, Rabin DL, Meyers DS, Bazemore AW. Projecting US primary care physician workforce needs: 2010-2025. *Ann Fam Med.* 2012;10(6):503-9. doi:10.1370/afm.1431
- 129
- 130 12. Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS. Association of Primary Care Physician Supply With Population Mortality in the United States, 2005-2015 Association of US Primary Care Physician Supply and Population Mortality Association of US Primary Care Physician Supply and Population Mortality. *JAMA Internal Medicine.* 2019;179(4):506-514. doi:10.1001/jamainternmed.2018.7624
- 131
- 132
- 133
- 134
- 135
- 136
- 137

- 138 13. Baillieu R, Kidd M, Phillips R, et al. The Primary Care Spend Model: A systems  
139 approach to measuring investment in primary care. *BMJ Glob Health*.  
140 2019;4(4):e001601. doi:10.1136/bmjgh-2019-001601
- 141 14. Reid R, Damberg C, Friedberg MW. Primary care spending in the fee-for-service  
142 medicare population. *JAMA Intern Med*. July 2019;179(7):977-980.  
143 doi:10.1001/jamainternmed.2018.8747
- 144 15. Cameron BJ, Bazemore AW, Morley CP. Lost in translation: NIH funding for  
145 family medicine research remains limited. *The Journal of the American Board of*  
146 *Family Medicine*. 2016;29(5):528. doi:10.3122/jabfm.2016.05.160063
- 147 16. DiLuccia, A. (2024, April 24). *Statewide Health Care Spending Target Approval is*  
148 *Key Step Towards Improving Health Care Affordability for Californians*. HCAI.  
149 [https://hcai.ca.gov/statewide-health-care-spending-target-approval-is-key-step-](https://hcai.ca.gov/statewide-health-care-spending-target-approval-is-key-step-towards-improving-health-care-affordability-for-californians/)  
150 [towards-improving-health-care-affordability-for-californians/](https://hcai.ca.gov/statewide-health-care-spending-target-approval-is-key-step-towards-improving-health-care-affordability-for-californians/)
- 151 17. Gilburg, M. L., & Gilburg, M. L. (2024, December 2). *Oregon's Cost Growth*  
152 *Target: Balancing Payer and Health System Accountability with Flexibility*.  
153 Milbank Memorial Fund. [https://www.milbank.org/2024/11/oregons-cost-growth-](https://www.milbank.org/2024/11/oregons-cost-growth-target-balancing-payer-and-health-system-accountability-with-flexibility/)  
154 [target-balancing-payer-and-health-system-accountability-with-flexibility/](https://www.milbank.org/2024/11/oregons-cost-growth-target-balancing-payer-and-health-system-accountability-with-flexibility/)
- 155 18. Baum, A., Song, Z., Landon, B. E., Phillips, R. S., Bitton, A., & Basu, S. (2019).  
156 Health care spending slowed after Rhode Island applied affordability standards to  
157 commercial insurers. *Health Affairs*, 38(2), 237–245.  
158 <https://doi.org/10.1377/hlthaff.2018.05164>
- 159 19. CHAPTER 20 – INSURANCE. (n.d.). In *TITLE 230 – DEPARTMENT OF*  
160 *BUSINESS REGULATION*. [https://ohic.ri.gov/sites/g/files/xkqbur736/files/2022-](https://ohic.ri.gov/sites/g/files/xkqbur736/files/2022-03/230-ricr-20-30-4-final-sos.pdf)  
161 [03/230-ricr-20-30-4-final-sos.pdf](https://ohic.ri.gov/sites/g/files/xkqbur736/files/2022-03/230-ricr-20-30-4-final-sos.pdf)
- 162 20. Primary Care Collaborative. (2021, July 2). *Delaware House passes bill that*  
163 *continues recent efforts to strengthen primary care system in the state - PCC*.  
164 PCC. [https://thepcc.org/news/delaware-house-passes-bill-that-continues-recent-](https://thepcc.org/news/delaware-house-passes-bill-that-continues-recent-efforts-to-strengthen-primary-care-system-in-the-state/)  
165 [efforts-to-strengthen-primary-care-system-in-the-state/](https://thepcc.org/news/delaware-house-passes-bill-that-continues-recent-efforts-to-strengthen-primary-care-system-in-the-state/)
- 166 21. 4-2-72 CONCERNING STRATEGIES TO INCREASE HEALTH INSURANCE  
167 AFFORDABILITY.pdf. (n.d.). Google Docs.  
168 <https://drive.google.com/file/d/19NzPs786iToCYw9XSQA0mzv10QfxTjED/view>

## 169 RELEVANT OSMA POLICY

### 170 Policy 18 – 2016 – Site of Service Charges

- 171
- 172
- 173 1. The OSMA requests that the American Medical Association continue to address  
174 the current inequity of “site of service” charges being used by hospitals and  
175 Medicare.

### 176 Policy 18 – 2019 – Practice Overhead Expense and the Site-of-Service Differential

- 177
- 178 1. The OSMA will appeal to the Ohio congressional delegation for legislation to  
179 direct CMS to eliminate any site-of-service differential payments to hospitals for  
180 the same service that can safely be performed in a doctor’s office.
- 181 2. The OSMA will appeal to the Ohio congressional delegation for legislation to  
182 direct CMS in regards to any savings to Part B Medicare, through elimination of  
183 the site-of-service differential payments to hospitals, (for the same service that

184 can safely be performed in a doctor's office), be distributed to all physicians who  
185 participate in Part B Medicare, by means of improved payments for office-based  
186 Evaluation and Management Codes, so as to immediately redress underpayment  
187 to physicians in regards to overhead expense.

188 3. The OSMA will appeal to the Ohio congressional delegation for legislation to  
189 direct CMS to make Medicare payments for the same service routinely and safely  
190 provided in multiple outpatient settings (e.g., physician offices, HOPDs and  
191 ASCs) that are based on sufficient and accurate data regarding the actual costs  
192 of providing the service in each setting.

193 4. This policy on practice overhead expense and site-of-service differential be  
194 forwarded to our AMA for consideration at the Annual HOD Meeting in June  
195 2019.

196

### 197 **Policy 18 – 2021 – Differential Payment**

198 1. The OSMA reaffirms existing policies 18-2016, site of service charges, and 18-  
199 2019, practice overhead expense and the site-of-service differential.

200

### 201 **Policy 20 – 2022 – Appropriate Physician Reimbursement to Cover Rising** 202 **Expenses of Office Practice**

203 1. The Ohio State Medical Association (OSMA) advocates that physician  
204 reimbursement for all activities be increased to cover the expenses of running an  
205 office practice.

206 2. The OSMA will work with our Ohio State Legislature and Ohio Congressional  
207 delegation to improve physician reimbursement.

208 3. The OSMA Delegation to the American Medical Association (AMA) shall take this  
209 resolution regarding improved physician reimbursement to the AMA House of  
210 Delegates for action.

211

### 212 **Policy 27 – 2023 -- Decrease Costs for Ohio Patients with Diabetes with** 213 **Commercial Insurance**

214 1. The OSMA will: (1) encourage the Ohio Department of Insurance to investigate  
215 insulin pricing and market competition and take enforcement actions as  
216 appropriate; (2) support initiatives that provide physician education regarding the  
217 cost-effectiveness of insulin therapies; and (3) support state efforts to limit the  
218 ultimate expenses incurred by commercially insured patients for prescribed  
219 insulin and diabetic equipment and supplies.

220

### 221 **Policy 6 – 2023 -- Increased Access to Health Care**

222 1. The OSMA continues to express its support for increased access to  
223 comprehensive, affordable, high-quality health care.

224 2. The OSMA rescinds current Policy 11 – 2010 – Promoting Free Market-Based  
225 Solutions to Health Care Reform.

226

### 227 **Policy 30 – 1994 – Increase in Number of Primary Care Physicians**

228 1. The OSMA supports positive incentives such as shifting of more subsidies to  
229 primary care medical education programs, increasing reimbursement levels, tax

230 abate­ments and loan repayment programs to attract greater numbers of primary  
231 care and rural physicians.

232 2. The OSMA discourages the enactment of restrictive measures such as licensure  
233 limitations, quotas in medical education programs, or compulsory measures  
234 which are intended to influence the numbers of primary care physicians in Ohio.  
235

### 236 **Policy 08 – 2013 – Support for More Primary Care Physicians**

237 1. The OSMA shall take steps to increase the number of medical students and  
238 residents going into primary care by calling for an increase in the number of  
239 residency positions in primary care.  
240

## 241 **RELEVANT AMA POLICY**

### 242 **Policy H-165.824: Improving Affordability in the Health Insurance Exchanges**

243 1. Our American Medical Association will:  
244 a. support adequate funding for and expansion of outreach efforts to  
245 increase public awareness of advance premium tax credits.  
246 b. support expanding eligibility for premium tax credits up to 500 percent of  
247 the federal poverty level.  
248 c. support providing young adults with enhanced premium tax credits while  
249 maintaining the current premium tax credit structure which is inversely  
250 related to income.  
251 d. encourage state innovation, including considering state-level individual  
252 mandates, auto-enrollment and/or reinsurance, to maximize the number of  
253 individuals covered and stabilize health insurance premiums without  
254 undercutting any existing patient protections.  
255 2. Our AMA supports:  
256 a. eliminating the subsidy "cliff", thereby expanding eligibility for premium tax  
257 credits beyond 400 percent of the federal poverty level (FPL).  
258 b. increasing the generosity of premium tax credits.  
259 c. expanding eligibility for cost-sharing reductions.  
260 d. increasing the size of cost-sharing reductions.  
261

### 262 **Policy H-165.888: Evaluating Health System Reform Proposals**

263 1. Our AMA will continue its efforts to ensure that health system reform proposals  
264 adhere to the following principles:  
265 a. Physicians maintain primary ethical responsibility to advocate for their  
266 patients' interests and needs.  
267 b. Unfair concentration of market power of payers is detrimental to patients  
268 and physicians, if patient freedom of choice or physician ability to select  
269 mode of practice is limited or denied. Single-payer systems clearly fall  
270 within such a definition and, consequently, should continue to be opposed  
271 by the AMA. Reform proposals should balance fairly the market power  
272 between payers and physicians or be opposed.  
273 c. All health system reform proposals should include a valid estimate of  
274 implementation cost, based on all health care expenditures to be included  
275 in the reform; and supports the concept that all health system reform

276 proposals should identify specifically what means of funding (including  
277 employer-mandated funding, general taxation, payroll or value-added  
278 taxation) will be used to pay for the reform proposal and what the impact  
279 will be.

280 d. All physicians participating in managed care plans and medical delivery  
281 systems must be able without threat of punitive action to comment on and  
282 present their positions on the plan's policies and procedures for medical  
283 review, quality assurance, grievance procedures, credentialing criteria,  
284 and other financial and administrative matters, including physician  
285 representation on the governing board and key committees of the plan.

286 e. Any national legislation for health system reform should include sufficient  
287 and continuing financial support for inner-city and rural hospitals,  
288 community health centers, clinics, special programs for special  
289 populations and other essential public health facilities that serve  
290 underserved populations that otherwise lack the financial means to pay for  
291 their health care.

292 f. Health system reform proposals and ultimate legislation should result in  
293 adequate resources to enable medical schools and residency programs to  
294 produce an adequate supply and appropriate generalist/specialist mix of  
295 physicians to deliver patient care in a reformed health care system.

296 g. All civilian federal government employees, including Congress and the  
297 Administration, should be covered by any health care delivery system  
298 passed by Congress and signed by the President.

299 h. True health reform is impossible without true tort reform.

300 2. Our AMA supports health care reform that meets the needs of all Americans  
301 including people with injuries, congenital or acquired disabilities, and chronic  
302 conditions, and as such values function and its improvement as key outcomes to  
303 be specifically included in national health care reform legislation.

304 3. Our AMA supports health care reform that meets the needs of all Americans  
305 including people with mental illness and substance use / addiction disorders and  
306 will advocate for the inclusion of full parity for the treatment of mental illness and  
307 substance use / addiction disorders in all national health care reform legislation.  
308 Our AMA supports health system reform alternatives that are consistent with AMA  
309 principles of pluralism, freedom of choice, freedom of practice, and universal  
310 access for patients.  
311



47 were otherwise equal, namely applicants who disclosed a history of depression had  
48 increased odds of being in a lower category of receiving an interview (OR = 3.60, p < .001  
49 for a “perfect” applicant, OR = 2.39, p < .001 for a “good” applicant with leave of absence)  
50 and a lower match ranking (OR = 1.94, p = .01 for a perfect applicant, OR = 2.30, p <  
51 .001 for a good applicant with leave of absence) compared with the candidate who  
52 disclosed a history of diabetes<sup>7</sup>; and

53  
54 **WHEREAS**, in alignment with 2023 policy from the AMA, some state medical  
55 boards have recently modified their licensure questions to be less intrusive and more  
56 focused on *current impairment* due to mental health conditions<sup>7, 8</sup>; and therefore be it

57  
58 **RESOLVED**, that the OSMA encourages Ohio medical schools to provide  
59 education to medical students on the process of mental health disclosures in residency  
60 applications.

61  
62  
63 **Fiscal Note:**           \$ 500+ (Sponsor)  
64                               \$ 500+ (Staff)

65  
66  
67 **References:**

68  
69 1. Kassam A, Antepim B, Sukhera J. A Mixed Methods Study of Perceptions of  
70 Mental Illness and Self-Disclosure of Mental Illness Among Medical Learners.  
71 *Perspect Med Educ.* 2024;13(1):336-348. Published 2024 Jun 5.  
72 doi:10.5334/pme.1152  
73 2. Dyrbye LN, West CP, Sinsky CA, Goeders LE, Satele DV, Shanafelt TD. Medical  
74 Licensure Questions and Physician Reluctance to Seek Care for Mental Health  
75 Conditions. *Mayo Clin Proc.* 2017;92(10):1486-1493.  
76 doi:10.1016/j.mayocp.2017.06.020  
77 3. Alfayez DI, AlShehri NA. Perceived Stigma Towards Psychological Illness in  
78 Relation to Psychological Distress Among Medical Students in Riyadh, Saudi  
79 Arabia. *Acad Psychiatry.* 2020;44(5):538-544. doi:10.1007/s40596-020-01247-4  
80 4. Aggarwal R, Coverdale J, Balon R, et al. To Disclose or Not: Residency Application  
81 and Psychiatric Illness. *Acad Psychiatry.* 2020;44(5):515-518.  
82 doi:10.1007/s40596-020-01296-9  
83 5. Shanafelt TD, Balch CM, Dyrbye L, et al. Special report: suicidal ideation among  
84 American surgeons. *Arch Surg.* 2011;146(1):54-62.  
85 doi:10.1001/archsurg.2010.292  
86 6. Guldner G, Siegel JT, Broadbent C, et al. Use of an Opt-Out vs Opt-In Strategy  
87 Increases Use of Residency Mental Health Services. *J Grad Med Educ.*  
88 2024;16(2):195-201. doi:10.4300/JGME-D-23-00460.1  
89 7. Pheister M, Peters RM, Wrzosek MI. The Impact of Mental Illness Disclosure in  
90 Applying for Residency. *Acad Psychiatry.* 2020;44(5):554-561.  
91 doi:10.1007/s40596-020-01227-8

- 92 8. Access to Confidential Health Services for Medical Students and Physicians H-  
93 295.858, Part 2, 2023 AMA.  
94  
95

96 **Relevant AMA and OSMA Policy:**  
97

98 **Access to Confidential Health Services for Medical Students and Physicians H-**  
99 **295.858**

- 100 1. Our American Medical Association will ask the Liaison Committee on Medical  
101 Education, Commission on Osteopathic College Accreditation, American  
102 Osteopathic Association, and Accreditation Council for Graduate Medical  
103 Education to encourage medical schools and residency/fellowship programs,  
104 respectively, to:  
105 a. provide or facilitate the immediate availability of urgent and emergent  
106 access to low-cost, confidential health care, including mental health and  
107 substance use disorder counseling services, that:  
108 i. include appropriate follow-up;  
109 ii. are outside the trainees' grading and evaluation pathways; and  
110 iii. are available (based on patient preference and need for assurance  
111 of confidentiality) in reasonable proximity to the education/training  
112 site, at an external site, or through telemedicine or other virtual,  
113 online means;  
114 b. ensure that residency/fellowship programs are abiding by all duty hour  
115 restrictions, as these regulations exist in part to ensure the mental and  
116 physical health of trainees;  
117 c. encourage and promote routine health screening among medical students  
118 and resident/fellow physicians, and consider designating some segment of  
119 already-allocated personal time off (if necessary, during scheduled work  
120 hours) specifically for routine health screening and preventive services,  
121 including physical, mental, and dental care; and  
122 d. remind trainees and practicing physicians to avail themselves of any  
123 needed resources, both within and external to their institution, to provide for  
124 their mental and physical health and well-being, as a component of their  
125 professional obligation to ensure their own fitness for duty and the need to  
126 prioritize patient safety and quality of care by ensuring appropriate self-care,  
127 not working when sick, and following generally accepted guidelines for a  
128 healthy lifestyle.  
129 2. *Our AMA will urge state medical boards to refrain from asking applicants about  
130 past history of mental health or substance use disorder diagnosis or treatment, and  
131 only focus on current impairment by mental illness or addiction, and to accept "safe  
132 haven" non-reporting for physicians seeking licensure or relicensure who are  
133 undergoing treatment for mental health or addiction issues, to help ensure  
134 confidentiality of such treatment for the individual physician while providing  
135 assurance of patient safety.*

- 136 3. Our AMA encourages undergraduate and graduate medical education programs  
137 to create mental health substance use awareness and suicide prevention  
138 screening programs that would:
- 139 a. be available to all medical students, residents, and fellows on an opt-out  
140 basis;
  - 141 b. ensure anonymity, confidentiality, and protection from administrative action;
  - 142 c. provide proactive intervention for identified at-risk students by mental health  
143 and addiction professionals; and
  - 144 d. inform students and faculty about personal mental health, substance use  
145 and addiction, and other risk factors that may contribute to suicidal ideation.
- 146 4. Our AMA:
- 147 a. encourages state medical boards to consider physical and mental  
148 conditions similarly;
  - 149 b. *encourages state medical boards to recognize that the presence of a mental  
150 health condition does not necessarily equate with an impaired ability to  
151 practice medicine; and*
  - 152 c. *encourages state medical societies to advocate that state medical boards  
153 not sanction physicians based solely on the presence of a psychiatric  
154 disease, irrespective of treatment or behavior.*
- 155 5. Our AMA:
- 156 a. encourages study of medical student mental health, including but not limited  
157 to rates and risk factors of depression and suicide;
  - 158 b. encourages medical schools to confidentially gather and release  
159 information regarding reporting rates of depression/suicide on an opt-out  
160 basis from its students; and
  - 161 c. will work with other interested parties to encourage research into identifying  
162 and addressing modifiable risk factors for burnout, depression and suicide  
163 across the continuum of medical education.
- 164 6. Our AMA encourages the development of alternative methods for dealing with the  
165 problems of student-physician mental health among medical schools, such as:
- 166 a. introduction to the concepts of physician impairment at orientation;
  - 167 b. ongoing support groups, consisting of students and house staff in various  
168 stages of their education;
  - 169 c. journal clubs;
  - 170 d. fraternities;
  - 171 e. support of the concepts of physical and mental well-being by heads of  
172 departments, as well as other faculty members; and/or
  - 173 f. the opportunity for interested students and house staff to work with students  
174 who are having difficulty. Our AMA supports making these alternatives  
175 available to students at the earliest possible point in their medical education.
- 176 7. Our AMA will engage with the appropriate organizations to facilitate the  
177 development of educational resources and training related to suicide risk of  
178 patients, medical students, residents/fellows, practicing physicians, and other  
179 health care professionals, using an evidence-based multidisciplinary approach.

182 Our AMA supports: (1) strategies that emphasize de-stigmatization and enable timely and  
183 affordable access to mental health services for undergraduate and graduate students, in  
184 order to improve the provision of care and increase its use by those in need; (2) colleges  
185 and universities in emphasizing to undergraduate and graduate students and parents the  
186 importance, availability, and efficacy of mental health resources; and (3) collaborations of  
187 university mental health specialists and local public or private practices and/or health  
188 centers in order to provide a larger pool of resources, such that any student is able to  
189 access care in a timely and affordable manner.

190

#### 191 **Access to Mental Health Services H-345.981**

192 Our AMA advocates the following steps to remove barriers that keep Americans from  
193 seeking and obtaining treatment for mental illness: (1) reducing the stigma of mental  
194 illness by dispelling myths and providing accurate knowledge to ensure a more informed  
195 public; (2) improving public awareness of effective treatment for mental illness; (3)  
196 ensuring the supply of psychiatrists and other well trained mental health professionals,  
197 especially in rural areas and those serving children and adolescents; (4) tailoring  
198 diagnosis and treatment of mental illness to age, gender, race, culture and other  
199 characteristics that shape a person's identity; (5) facilitating entry into treatment by first-  
200 line contacts recognizing mental illness, and making proper referrals and/or to addressing  
201 problems effectively themselves; and (6) reducing financial barriers to treatment.

202



47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

**RESOLVED**, our Ohio State Medical Association advocate for legislation or regulation mandating all cannabinoid products sold legally by licensed marijuana dispensaries in the State of Ohio be sold to consumers in child-resistant packaging; and be it further

**RESOLVED**, and be it further resolved that our Ohio State Medical Association advocate for a database of cannabinoid positive screenings in children under age 18 be established in the state of Ohio to establish trends in marijuana use and accidental ingestion.

**Fiscal Note:**           \$ 50,000 (Sponsor)  
                                  \$ 50,000 (Staff)

**References:**

1. *House Bill 523 (2016) House Bill 523 | 131st General Assembly | Ohio Legislature*. Available at: <https://www.legislature.ohio.gov/legislation/131/hb523> (Accessed: 05 February 2025). O
2. Ohio Ballot Board. *Issue 2 Certified Language*. Ohio Secretary of State; August 24, 2023. Accessed [Date you accessed the document].  
<https://www.ohiosos.gov/globalassets/ballotboard/2023/issue-2-certified-language---08-24-23.pdf>
3. Wang, G. S., Narang, S. K., Wells, K., & Chuang, R. (2011). A case series of marijuana exposures in pediatric patients less than 5 years of age. *Child Abuse & Neglect*, 35(7), 563–565. <https://doi.org/10.1016/j.chiabu.2011.03.012>
4. Macnab, A., Anderson, E., & Susak, L. (1989). Ingestion of cannabis A Cause of coma in children. *Pediatric Emergency Care*, 5(4), 238–239.  
<https://doi.org/10.1097/00006565-198912000-00010>
5. Heizer, J. W., Borgelt, L. M., Bashqoy, F., Wang, G. S., & Reiter, P. D. (2018). Marijuana misadventures in children. *Pediatric Emergency Care*, 34(7), 457–462.  
<https://doi.org/10.1097/pec.0000000000000770>
6. Richards, J. R., Smith, N. E., & Moulin, A. K. (2017). Unintentional cannabis ingestion in children: A systematic review. *The Journal of Pediatrics*, 190, 142–152. <https://doi.org/10.1016/j.jpeds.2017.07.005>
7. Whitehill, J. M., Harrington, C., Lang, C. J., Chary, M., Bhutta, W. A., & Burns, M. M. (2019). Incidence of pediatric cannabis exposure among children and teenagers aged 0 to 19 years before and after medical marijuana legalization in Massachusetts. *JAMA Network Open*, 2(8).  
<https://doi.org/10.1001/jamanetworkopen.2019.9456>
8. Wang, G. S., Le Lait, M.-C., Deakyne, S. J., Bronstein, A. C., Bajaj, L., & Roosevelt, G. (2016). Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. *JAMA Pediatrics*, 170(9).  
<https://doi.org/10.1001/jamapediatrics.2016.0971>
9. Cao, D., Srisuma, S., Bronstein, A. C., & Hoyte, C. O. (2016). Characterization of edible marijuana product exposures reported to United States Poison Centers.

93           *Clinical Toxicology*, 54(9), 840–846.  
94           <https://doi.org/10.1080/15563650.2016.1209761>  
95       10. Marit S. Tweet, Antonia Nemanich, Michael Wahl; Pediatric Edible Cannabis  
96           Exposures and Acute Toxicity: 2017–2021. *Pediatrics* 2023; e2022057761.  
97           10.1542/peds.2022-057761f  
98       11. Kowitt, S. D., Yockey, R. A., Lee, J. G. L., Jarman, K. L., Gourdet, C. K., &  
99           Ranney, L. M. (2022). The Impact of Cannabis Packaging Characteristics on  
100           Perceptions and Intentions. *American journal of preventive medicine*, 63(5), 751–  
101           759. <https://doi.org/10.1016/j.amepre.2022.04.030>  
102  
103



47  
48       **WHEREAS**, marijuana usage has increased significantly in youth populations, and  
49 the development of schizophrenia and psychosis in adolescence is more likely given that  
50 the risk also is dependent on the dosage consumed<sup>11</sup>; and

51  
52       **WHEREAS**, usage of cannabis by pregnant and breast-feeding women increases  
53 the risk of the fetus and newborn developing neuropsychiatric conditions, predominantly  
54 those related to the limbic system, later on in life<sup>12</sup>; and

55  
56       **WHEREAS**, a recent study found that pharmacy students in Ohio did not feel  
57 adequately prepared to counsel their patients on the usage of medical marijuana,  
58 especially due to the lack of a solid structured curriculum within current medical education  
59 on the subject<sup>13</sup>; and therefore be it

60  
61       **RESOLVED**, That our OSMA amend Policy 07 - 2016 by addition and deletion:

62  
63       **Policy 07 – 2016 – Cannabinoids**

- 64       1. The OSMA opposes recreational use of cannabis.  
65       2. The OSMA supports Institutional Review Board (IRB) approved clinical research to  
66       explore the potential risks versus benefits of using cannabinoids to treat specific  
67       medical conditions.  
68       3. The OSMA supports focused and controlled medical use of pharmaceutical grade  
69       cannabinoids for treatment of those conditions which have been evaluated through  
70       Institutional Review Board (IRB) approved clinical research studies and have been  
71       shown to be efficacious.  
72       4. The OSMA recommends that marijuana’s status as a federal Schedule I controlled  
73       substance be reviewed with the goal of facilitating the conduct of clinical research  
74       and development of cannabinoid-based medicines and alternate delivery methods.  
75       5. The OSMA supports limiting cannabinoids prescribing rights, ~~if permitted~~, to  
76       physicians (MDs and DOs).  
77       6. The OSMA opposes legalization of any presently illegal drugs of substance abuse  
78       including, but not limited to, cannabis and cocaine, except in the instance of  
79       appropriate evidence based use approved by the FDA.  
80       7. The OSMA encourages physician participation in future legislative and regulatory  
81       discussions regarding the legal use of cannabinoids.  
82       8. The OSMA will support urgent regulatory and legislative changes necessary to fund  
83       and perform research related to cannabis and cannabinoids.  
84       9. The OSMA supports state initiatives to regulate recreational and medicinal  
85       marijuana effectively in order to protect public health and safety including but not  
86       limited to: regulating retail sales, marketing, and promotion intended to encourage  
87       use; limiting the potency of cannabis extracts and concentrates; requiring  
88       packaging to convey meaningful and easily understood units of consumption, and  
89       requiring that for commercially available edibles, packaging must be child-resistant  
90       and come with messaging about the hazards about unintentional ingestion in  
91       children and youth.

- 92 10. The OSMA encourages local and state public health agencies to improve  
93 surveillance efforts to ensure data is available on the short- and long-term health  
94 effects of cannabis, especially emergency department visits and hospitalizations,  
95 impaired driving, workplace impairment and worker-related injury and safety, and  
96 prevalence of psychiatric and addictive disorders, including cannabis use disorder.  
97 11. The OSMA will support stronger public health messaging on the health effects of  
98 cannabis and cannabinoid inhalation and ingestion, with an emphasis on reducing  
99 initiation and frequency of cannabis use among adolescents, especially high  
100 potency products; use among people who are pregnant or contemplating  
101 pregnancy; and avoiding cannabis-impaired driving.

102  
103  
104 Fiscal Note                 \$500+ (Sponsor)  
105                                     \$500+ (Staff)

106  
107  
108 **References:**

- 109 1. Henry, M. (2023, November 8). *Ohioans vote to legalize recreational marijuana by*  
110 *passing Issue 2 law*. Ohio Capital Journal.  
111 2. Keating Muething & Klekamp PLL. (2024, April 23). *A post Issue 2 update on*  
112 *recreational marijuana in Ohio*.  
113 3. Detrano, J. Cannabis Black Market Thrives Despite Legalization. *Rutgers-New*  
114 *Brunswick Center of Alcohol and Substance Use Studies*.  
115 4. Arnold S, Goldman J. In many states, the cannabis black market may thrive when  
116 prices get too high. *Columbia Missourian*. Jun 22, 2023.  
117 5. Gwinn KD, Leung MC, Stephens A., Punja ZK. Fungal and mycotoxin contaminants  
118 in cannabis and hemp flowers: implications for consumer health and directions for  
119 further research. *Frontiers in Microbiology*. 2023; 14. doi: 10.3389  
120 6. Miller OS, Elder EJ Jr, Jones KJ, Gidal BE. Analysis of cannabidiol (CBD) and THC  
121 in nonprescription consumer products: Implications for patients and practitioners.  
122 *Epilepsy Behav*. 2022;127:108514. doi:10.1016/j.yebeh.2021.108514  
123 7. Dryburgh LM, Bolan NS, Grof CPL, et al. Cannabis contaminants: sources,  
124 distribution, human toxicity and pharmacologic effects. *Br J Clin Pharmacol*.  
125 2018;84(11):2468-2476. doi:10.1111/bcp.13695  
126 8. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence.  
127 *Curr Pharm Des*. 2011;17(14):1351-1358. doi:10.2174/138161211796150846  
128 9. Gallagher TJ, Chung RS, Lin ME, Kim I, Kokot NC. Cannabis Use and Head and  
129 Neck Cancer. *JAMA Otolaryngol Head Neck Surg*. 2024;150(12):1068-1075.  
130 doi:10.1001/jamaoto.2024.2419  
131 10. Kaplan AG. Cannabis and Lung Health: Does the Bad Outweigh the Good?. *Pulm*  
132 *Ther*. 2021;7(2):395-408. doi:10.1007/s41030-021-00171-8  
133 11. Ladegard K, Thurstone C, Rylander M. Marijuana Legalization and Youth. *Pediatrics*  
134 May 2020; 145 (Supplement\_2): S165–S174. 10.1542/peds.2019-2056D  
135 12. Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Femenía T,  
136 Manzanares J. Cannabis Use in Pregnant and Breastfeeding Women: Behavioral

137 and Neurobiological Consequences. *Frontiers in Psychiatry*. 2020;11.  
138 doi:10.3389/fpsy.2020.586447  
139 13. Zolotov Y, Metri S, Calabria E, Kogan M. Medical cannabis education among  
140 healthcare trainees: A scoping review. *Complementary Therapies in Medicine*. 2021;  
141 58.

142 **Relevant OSMA Policy:**

143 **Policy 07 – 2016 – Cannabinoids**

1441. The OSMA opposes recreational use of cannabis.  
1452. The OSMA supports limiting cannabinoids prescribing rights, if permitted, to physicians  
146 (MDs and DOs).  
1473. The OSMA opposes legalization of any presently illegal drugs of substance abuse  
148 including, but not limited to, cannabis and cocaine, except in the instance of appropriate  
149 evidence based use approved by the FDA.

150

151 **Policy 31 – 2024 -- Encourage Cannabis Counseling and Harm Reduction**

- 152 1. OSMA encourages physicians to be informed regarding risks, benefits, and harm  
153 reduction techniques related to cannabis use.

154

155

156

157

158

159 **Relevant AMA Policy:**

160

161 **Cannabis and Cannabinoid Research H-95.952**

1621. Our American Medical Association calls for further adequate and well-controlled studies  
163 of marijuana and related cannabinoids in patients who have serious conditions for which  
164 preclinical, anecdotal, or controlled evidence suggests possible efficacy and the  
165 application of such results to the understanding and treatment of disease.  
1662. Our AMA urges that marijuana's status as a federal schedule I controlled substance be  
167 reviewed with the goal of facilitating the conduct of clinical research and development of  
168 cannabinoid-based medicines, and alternate delivery methods. This should not be  
169 viewed as an endorsement of state-based medical cannabis programs, the legalization  
170 of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the  
171 current standards for a prescription drug product.  
1723. Our AMA urges the National Institutes of Health (NIH), the Drug Enforcement  
173 Administration (DEA), and the Food and Drug Administration (FDA) to develop a special  
174 schedule and implement administrative procedures to facilitate grant applications and  
175 the conduct of well-designed clinical research involving cannabis and its potential  
176 medical utility. This effort should include:  
177a. disseminating specific information for researchers on the development of safeguards for  
178 cannabis clinical research protocols and the development of a model informed consent  
179 form for institutional review board evaluation;  
180b. sufficient funding to support such clinical research and access for qualified investigators  
181 to adequate supplies of cannabis for clinical research purposes;

- 182c. confirming that cannabis of various and consistent strengths and/or placebo will be  
183 supplied by the National Institute on Drug Abuse to investigators registered with the  
184 DEA who are conducting bona fide clinical research studies that receive FDA approval,  
185 regardless of whether or not the NIH is the primary source of grant support.
1864. Our AMA supports research to determine the consequences of long-term cannabis use,  
187 especially among youth, adolescents, pregnant women, and women who are  
188 breastfeeding.
1895. Our AMA urges legislatures to delay initiating the legalization of cannabis for  
190 recreational use until further research is completed on the public health, medical,  
191 economic, and social consequences of its use.
1926. Our AMA will advocate for urgent regulatory and legislative changes necessary to fund  
193 and perform research related to cannabis and cannabinoids.
- 194 Our AMA will create a Cannabis Task Force to evaluate and disseminate relevant  
195 scientific evidence to health care providers and the public.
- 196



46           **WHEREAS**, a systematic literature review of 59 studies found that 11% of  
47 screened patients indicated they were experiencing intimate partner violence (IPV), with  
48 32% of patients receiving a referral to follow-up organizations<sup>9</sup>; and  
49

50           **WHEREAS**, routine screening for IPV ranges from 3% to 10%, despite the fact  
51 that counseling has been shown to reduce stigma around conversations about IPV and  
52 IPV victimization<sup>10</sup>; and  
53

54           **WHEREAS**, providers often acknowledge the importance of intimate partner  
55 violence screening, yet routine screening rates by providers remain low<sup>11</sup>; and  
56

57           **WHEREAS**, screening for IPV can connect victims of IPV to resources like  
58 housing and child care, empower them and promote self-efficacy, and improve their  
59 well-being and safety<sup>12</sup>; and  
60

61           **WHEREAS**, current AMA Policy H-515.965 acknowledges family and intimate  
62 partner violence to be major public health issues and believes that all physicians should  
63 be trained to identify situations of domestic violence and help patients in safety  
64 planning<sup>13</sup>; therefore be it  
65

66           **RESOLVED**, that our OSMA supports comprehensive training on intimate  
67 partner violence screening for medical students, residents, and physicians in Ohio.  
68

69 Fiscal Note:           \$500+ (Sponsor)  
70                               \$500+ (Staff)  
71

72 **References:**  
73

- 74 1. United Nations. What Is Domestic Abuse? United Nations. Published 2024.  
75 <https://www.un.org/en/coronavirus/what-is-domestic-abuse>  
76 2. Leemis R.W., Friar N., Khatiwada S., Chen M.S., Kresnow M., Smith S.G., Caslin, S.,  
77 & Basile, K.C. (2022). *The National Intimate Partner and Sexual Violence Survey:  
78 2016/2017 Report on Intimate Partner Violence*. Atlanta, GA: National Center for Injury  
79 Prevention and Control, Centers for Disease Control and Prevention.  
80 3. Walker-Descartes I, Mineo M, Condado LV, Agrawal N. Domestic Violence and Its  
81 Effects on Women, Children, and Families. *Pediatr Clin North Am*. 2021;68(2):455-464.  
82 doi:10.1016/j.pcl.2020.12.011  
83 4. Ohio Domestic Violence Fatalities July 1, 2023 - June 30, 2024. Ohio Domestic  
84 Violence Network. Published October 2024. Accessed November 22, 2024.  
85 <https://www.odvn.org/wp-content/uploads/2024/10/Fatality-Infographic-2024.pdf>  
86 5. Ohio Bureau of Criminal Identification and Investigation. (2023) *Domestic Violence  
87 Report*. [https://www.ohioattorneygeneral.gov/Files/Reports/Domestic-Violence-  
88 Reports/Domestic-Violence-Reports-2023/2023-Domestic-Violence-Incidents-by-  
89 County-and-Age](https://www.ohioattorneygeneral.gov/Files/Reports/Domestic-Violence-Reports/Domestic-Violence-Reports-2023/2023-Domestic-Violence-Incidents-by-County-and-Age)  
90 6. Dicola D, Spaar E. Intimate Partner Violence. *Am Fam Physician*. 2016;94(8):646-  
91 651.

- 92 7. USPSTF. Recommendation | United States Preventive Services Taskforce.  
93 www.uspreventiveservicestaskforce.org. Published October 23, 2018.  
94 [https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening)  
95 [violence-and-abuse-of-elderly-and-vulnerable-adults-screening](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening)  
96 8..Committee on Health Care for Underserved Women. Intimate partner violence.  
97 www.acog.org. Published 2022. [https://www.acog.org/clinical/clinical-](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/02/intimate-partner-violence)  
98 [guidance/committee-opinion/articles/2012/02/intimate-partner-violence](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/02/intimate-partner-violence)  
99 9. Miller CJ, Adjognon OL, Brady JE, Dichter ME, Iverson KM. Screening for intimate  
100 partner violence in healthcare settings: An implementation-oriented systematic review.  
101 Implementation Research and Practice. 2021; 2. doi: 10.1177/26334895211039894  
102 10. Singh V, Petersen K, Singh SR. Intimate partner violence victimization: identification  
103 and response in primary care. Prim Care. 2014;41(2):261-281.  
104 doi:10.1016/j.pop.2014.02.005  
105 11. Alvarez C, Fedock G, Grace KT, Campbell J. Provider Screening and Counseling  
106 for Intimate Partner Violence: A Systematic Review of Practices and Influencing  
107 Factors. Trauma, Violence, & Abuse. 2017;18(5):479-495.  
108 doi:10.1177/1524838016637080  
109 12. Bair-Merritt MH, Lewis-O'Connor A, Goel S, et al. Primary care-based interventions  
110 for intimate partner violence: a systematic review. Am J Prev Med. 2014;46(2):188-194.  
111 doi:10.1016/j.amepre.2013.10.001  
112 13. AMA Policy H-515.965: Family and Intimate Partner Violence. American Medical  
113 Association.

#### 114 115 116 Relevant OSMA Policy

#### 117 118 **Policy 24– 2023 -- Coverage of Restorative Care for Survivors of Domestic Abuse** 119 **or Intimate Partner Violence**

120 1. The OSMA urges all payers to consider any  
121 reconstructive medical and dental treatments for physical injury sustained from or  
122 directly related to domestic and intimate partner violence as restorative treatments. 2.  
123 The OSMA will work with relevant stakeholders such as the American Medical  
124 Association and the Centers for Medicare and Medicaid Service to encourage payers to  
125 cover costs associated with reconstructive treatments for physical injury sustained from  
126 abuse for survivors of domestic and/or intimate partner violence or abuse. 3. The OSMA  
127 supports legislation by the Ohio General Assembly to require all third-party payers,  
128 including Medicaid MCOs, to reimburse reconstructive services provided for treatment  
129 of physical injury in addition to the medically-necessary restorative care provided to  
130 victims of domestic and intimate partner abuse.

#### 131 Relevant AMA Policy

#### 132 **Family and Intimate Partner Violence H-515.965**

133 (1) Our AMA believes that all forms of family and intimate partner violence (IPV) are  
134 major public health issues and urges the profession, both individually and collectively, to  
135 work with other interested parties to prevent such violence and to address the needs of  
136 survivors. Physicians have a major role in lessening the prevalence, scope and severity  
137 of child maltreatment, intimate partner violence, and elder abuse, all of which fall under

138 the rubric of family violence. To support physicians in practice, our AMA will continue to  
139 campaign against family violence and remains open to working with all interested  
140 parties to address violence in US society.

141 (2) Our AMA believes that all physicians should be trained in issues of family and  
142 intimate partner violence through undergraduate and graduate medical education as  
143 well as continuing professional development. The AMA, working with state, county and  
144 specialty medical societies as well as academic medical centers and other appropriate  
145 groups such as the Association of American Medical Colleges, should develop and  
146 disseminate model curricula on violence for incorporation into undergraduate and  
147 graduate medical education, and all parties should work for the rapid distribution and  
148 adoption of such curricula. These curricula should include coverage of the diagnosis,  
149 treatment, and reporting of child maltreatment, intimate partner violence, and elder  
150 abuse and provide training on interviewing techniques, risk assessment, safety  
151 planning, and procedures for linking with resources to assist survivors. Our AMA  
152 supports the inclusion of questions on family violence issues on licensure and  
153 certification tests.

154 (3) The prevalence of family violence is sufficiently high and its ongoing character is  
155 such that physicians, particularly physicians providing primary care, will encounter  
156 survivors on a regular basis. Persons in clinical settings are more likely to have  
157 experienced intimate partner and family violence than non-clinical populations. Thus, to  
158 improve clinical services as well as the public health, our AMA encourages physicians  
159 to: (a) Routinely inquire about the family violence histories of their patients as this  
160 knowledge is essential for effective diagnosis and care; (b) Upon identifying patients  
161 currently experiencing abuse or threats from intimates, assess and discuss safety  
162 issues with the patient before he or she leaves the office, working with the patient to  
163 develop a safety or exit plan for use in an emergency situation and making appropriate  
164 referrals to address intervention and safety needs as a matter of course; (c) After  
165 diagnosing a violence-related problem, refer patients to appropriate medical or health  
166 care professionals and/or community-based trauma-specific resources as soon as  
167 possible; (d) Have written lists of resources available for survivors of violence, providing  
168 information on such matters as emergency shelter, medical assistance, mental health  
169 services, protective services and legal aid; (e) Screen patients for psychiatric sequelae  
170 of violence and make appropriate referrals for these conditions upon identifying a  
171 history of family or other interpersonal violence; (f) Become aware of local resources  
172 and referral sources that have expertise in dealing with trauma from IPV; (g) Be alert to  
173 men presenting with injuries suffered as a result of intimate violence because these  
174 men may require intervention as either survivors or abusers themselves; (h) Give due  
175 validation to the experience of IPV and of observed symptomatology as possible  
176 sequelae; (i) Record a patient's IPV history, observed traumata potentially linked to IPV,  
177 and referrals made; (j) Become involved in appropriate local programs designed to  
178 prevent violence and its effects at the community level.

179 (4) Within the larger community, our AMA:

180 (a) Urges hospitals, community mental health agencies, and other helping professions  
181 to develop appropriate interventions for all survivors of intimate violence. Such  
182 interventions might include individual and group counseling efforts, support groups, and  
183 shelters.

184 (b) Believes it is critically important that programs be available for survivors and  
185 perpetrators of intimate violence.

186 (c) Believes that state and county medical societies should convene or join state and  
187 local health departments, criminal justice and social service agencies, and local school  
188 boards to collaborate in the development and support of violence control and prevention  
189 activities.

190 (5) With respect to issues of reporting, our AMA strongly supports mandatory reporting  
191 of suspected or actual child maltreatment and urges state societies to support  
192 legislation mandating physician reporting of elderly abuse in states where such  
193 legislation does not currently exist. At the same time, our AMA oppose the adoption of  
194 mandatory reporting laws for physicians treating competent, non-elderly adult survivors  
195 of intimate partner violence if the required reports identify survivors. Such laws violate  
196 basic tenets of medical ethics. If and where mandatory reporting statutes dealing with  
197 competent adults are adopted, the AMA believes the laws must incorporate provisions  
198 that: (a) do not require the inclusion of survivors' identities; (b) allow competent adult  
199 survivors to opt out of the reporting system if identifiers are required; (c) provide that  
200 reports be made to public health agencies for surveillance purposes only; (d) contain a  
201 sunset mechanism; and (e) evaluate the efficacy of those laws. State societies are  
202 encouraged to ensure that all mandatory reporting laws contain adequate protections  
203 for the reporting physician and to educate physicians on the particulars of the laws in  
204 their states.

205 (6) Substance abuse and family violence are clearly connected. For this reason, our  
206 AMA believes that:

207 (a) Given the association between alcohol and family violence, physicians should be  
208 alert for the presence of one behavior given a diagnosis of the other. Thus, a physician  
209 with patients with alcohol problems should screen for family violence, while physicians  
210 with patients presenting with problems of physical or sexual abuse should screen for  
211 alcohol use.

212 (b) Physicians should avoid the assumption that if they treat the problem of alcohol or  
213 substance use and abuse they also will be treating and possibly preventing family  
214 violence.

215 (c) Physicians should be alert to the association, especially among female patients,  
216 between current alcohol or drug problems and a history of physical, emotional, or sexual  
217 abuse. The association is strong enough to warrant complete screening for past or  
218 present physical, emotional, or sexual abuse among patients who present with alcohol  
219 or drug problems.

220 (d) Physicians should be informed about the possible pharmacological link between  
221 amphetamine use and human violent behavior. The suggestive evidence about  
222 barbiturates and amphetamines and violence should be followed up with more research  
223 on the possible causal connection between these drugs and violent behavior.

224 (e) The notion that alcohol and controlled drugs cause violent behavior is pervasive  
225 among physicians and other health care providers. Training programs for physicians  
226 should be developed that are based on empirical data and sound theoretical  
227 formulations about the relationships among alcohol, drug use, and violence.

228 **Promoting Physician Awareness of the Correlation Between Domestic Violence**  
229 **and Child Abuse D-515.982** (Our American Medical Association will work with

230 members of the Federation of Medicine and other appropriate organizations to educate  
231 physicians on (1) the relationship between domestic violence and child abuse and (2)  
232 the appropriate role of the physician in treating patients when domestic violence and/or  
233 child abuse are suspected.)

234

235 **Education of Medical Students and Residents about Domestic Violence Screening**  
236 **H-295.912** (Our American Medical Association will continue its support for the education  
237 of medical students and residents on domestic violence by advocating that medical  
238 schools and graduate medical education programs educate students and resident  
239 physicians to sensitively inquire about family abuse with all patients, when appropriate  
240 and as part of a comprehensive history and physical examination, and provide  
241 information about the available community resources for the management of the  
242 patient.)



1. Seino, Y, Fukushima, M., & Tabe, D. (2010). GIP and GLP-1, the two incretin hormones: Similarities and differences. *Journal of Diabetes Investigation*. 1:12, 8-23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/>
2. FDA-approved label for Ozempic (Semaglutide): [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/209637s020s021lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf)
3. FDA-approved label for Zepbound (Tirzepatide): [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/217806s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf)
4. Cubanski, J, Neuman, T. & Sroczynski. (2024). A new use for Wegovy open the door to Medicare coverage for millions of people with obesity. *Kaiser Family Foundation Issue Brief*. <https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/>
5. Sodhi, M, Rezaeianzadeh, R., & Kezouh, A. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. *JAMA*. 330(18): 1795-1797. <https://jamanetwork.com/journals/jama/fullarticle/2810542>
6. Joshi, G.P, Abdelmalak, B.B., Weigel, W.A., Soriano, S.G., Harbell, M.W., Kuo, C.I., Stricker, P.A., Domino, K.B. (2023). American Society of Anesthesiologists consensus-based guidance on perioperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. *American Society of Anesthesiologists Press Release*: June 29, 2023. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>
7. Niewijk, G. (2024). Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns. *University of Chicago Medicine Press Release*: May 30, 2024. <https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/2024/may/research-on-glp-1-drugs>
8. Cassata, C. (2023). Ozempic can cause major loss of muscle mass and reduce bone density. *Healthline*: May 2, 2023. <https://www.healthline.com/health-news/ozempic-muscle-mass-loss>
9. Daniel, K. (2024). What older adults need to know before taking a GLP-1 like Ozempic. *Everyday Health*: May 17, 2024. <https://www.everydayhealth.com/obesity/what-older-adults-need-to-know-before-taking-a-glp-1-like-ozempic/>



48

49 **Fiscal Note:** \$ 10,000 (Sponsor)

50 \$ \$25,000- \$500,000 (Staff)

51

52 **References:**

53

54 1. OSMA Policy Compendium, 2024 Edition

55 2. "The Hidden Costs of Compliance: A Survey of Physician Time Allocation,"  
56 Journal of Medical Economics, 2023

57 3. Ohio Hospital Association Annual Report, 2024



47           **WHEREAS**, the physician owned hospital ban eliminates the benefits of  
48 integrated, coordinated care delivery observed in vertically oriented self-referral models  
49 (8); and

50  
51           **WHEREAS**, benefits of self-referral within integrated delivery models include  
52 concepts of one stop shop, improved sharing of clinical information, better care delivery  
53 experience by consumers (7,8); and

54  
55           **WHEREAS**, reversing the ACA-imposed ban on new construction or expansion of  
56 existing POHs will stimulate greater competition and provide patients with another option  
57 to receive high quality health care services (7,8); and therefore be it

58  
59           **RESOLVED**, our OSMA will advocate for policies that restore physician’s options  
60 of owning, expanding, and/or constructing any form of hospital; and be it further

61  
62           **RESOLVED**, our OSMA will advocate for policies that enable the highest quality  
63 of patient care including the removal of barriers to physician’s owning hospitals as is found  
64 in H.R. 977 and S. 470 known as “Patient Access to Higher Quality Health Care Act of  
65 2023”; and be it further

66  
67           **RESOLVED**, our OSMA will work to educate its members and the public on the  
68 potential benefits of physician owned hospitals as well as the need for policies that will  
69 support and promote physician hospital ownership; and be it further

70  
71           **RESOLVED**, our OSMA will collaborate with the AMA and other stakeholders to  
72 develop and promote policies that support physician ownership of hospitals.

73  
74

75   **Fiscal Note**                 \$ 5,000 (Sponsor)  
76   \$ 25,000- \$500,000 (Staff)

77  
78   **References:**

79  
80           1. Martin Gaynor. Antitrust Applied: Hospital consolidation concerns and  
81           Solution. Statement before the Committee on the Judiciary Subcommittee on  
82           Competition Policy, antitrust, and Consumer rights. US Senate Washington DC  
83           May 19, 2021  
84           2. Taylor LA (2023). Review of Dranove and Burns 2021. Big Med: Megaproviders  
85           and the high cost of healthcare in America. Cambridge quarterly of healthcare  
86           ethics; CQ: the international Journal of healthcare ethics Committees, 32(2) 300-  
87           304  
88           3. Zach Cooper, Martin Gaynor. Addressing Hospital concentration and rising  
89           consolidation in the United States. [Onepercentsteps.com](http://Onepercentsteps.com)  
90           4. Cooper, Zack et al. The Price ain’t Right? Hospital prices and Health spending  
91           on the privately insured. The quarterly Journal of Economics vol 134,1  
92           (2019):51-107

- 93 5. Arnold , Daniel & Whaley, Christopher (2020). Who pays for Health care costs?  
94 The effects of healthcare prices on wages. SSRN Electronic Journal.  
95 10.2139/ssrn.3657598
- 96 6. Frakt AB. Hospital Consolidation Isn't the Key to Lowering Costs and Raising  
97 Quality. *JAMA*. 2015;313(4):345. doi:10.1001/jama.2014.17412
- 98 7. REPORT OF THE COUNCIL ON MEDICAL SERVICE: CMS Report 4-I-23  
99 Subject: Physician-Owned Hospitals Presented by: Sheila Rege, MD, Chair.
- 100 8. Brian J. Miller, Robert E. Moffit, James Ficke, Joseph Marine, Jesse Ehrenfeld  
101 APRIL 12, 2021. Reversing Hospital Consolidation: The Promise Of Physician-  
102 Owned Hospitals. [HTTPS://www.aaos.org](https://www.aaos.org) >globalassets>advocacy  
103



- 47 2. <https://codes.ohio.gov/ohio-revised-code/section-4513.263>
- 48 3. [https://www.axios.com/local/columbus/2024/04/16/ohio-seat-belt-laws-governor-](https://www.axios.com/local/columbus/2024/04/16/ohio-seat-belt-laws-governor-dewine)
- 49 [dewine](https://www.axios.com/local/columbus/2024/04/16/ohio-seat-belt-laws-governor-dewine)
- 50 4. <https://www.ghsa.org/state-laws/issues/Seat%20Belts?state=Ohio>
- 51 5. [https://www.axios.com/local/columbus/2023/10/23/drivers-seat-belt-usage-report-](https://www.axios.com/local/columbus/2023/10/23/drivers-seat-belt-usage-report-low-down-buckle-up)
- 52 [low-down-buckle-up](https://www.axios.com/local/columbus/2023/10/23/drivers-seat-belt-usage-report-low-down-buckle-up)
- 53 6. <https://fox8.com/news/seat-belt-law-could-soon-change-in-ohio/>
- 54



47           **WHEREAS**, several research studies have demonstrated that PFAS can penetrate  
48 the blood-brain barrier and accumulate in both infant and adult brains<sup>8</sup>; and  
49

50           **WHEREAS**, PFAS have been found to pass through the placenta via the mother's  
51 bloodstream, and additional research indicates that prolonged exposure to these  
52 chemicals can raise the risk of neurodevelopmental delays and future motor function  
53 issues<sup>9</sup>; and  
54

55           **WHEREAS**, the diversity and complexity of PFAS chemicals present challenges  
56 in clinical recognition, intervention, and toxicity assessment, as the biological effects of  
57 PFAS may vary by sex, species, and life stage, complicating clinical recognition and  
58 intervention<sup>10</sup>; and  
59

60           **WHEREAS**, PFAS toxicity is not linked to specific signs or symptoms, so patients  
61 with known exposure may be asymptomatic, show signs of other health issues, or be  
62 uncertain of their exposure despite living in an affected community<sup>11</sup>; and  
63

64           **WHEREAS**, there are no approved medical treatments available to remove PFAS  
65 in the body<sup>11</sup>; and  
66

67           **WHEREAS**, many factors play into the possible development of symptoms due to  
68 PFAS exposure, which includes the duration, frequency, and the amount of PFAS they  
69 were exposed to at any given time<sup>12</sup>; and  
70

71           **WHEREAS**, in deciding whether to order PFAS blood testing, clinicians can take  
72 into account an individual's exposure history, such as the patient's water supply, food, or  
73 other pathways, and determine if the results could help guide exposure reduction and  
74 health promotion when deciding whether to order testing<sup>13</sup>; and  
75

76           **WHEREAS**, patients and clinicians can weigh the risks and benefits of using PFAS  
77 blood test results to guide care, considering factors like disease risk, the need for extra  
78 screenings, and the potential for false positives leading to unnecessary tests or  
79 treatments<sup>13</sup>; and  
80

81           **WHEREAS**, individuals may be unknowingly exposed to PFAS, including industrial  
82 workers in factories where PFAS are present and people living near PFAS-producing  
83 facilities<sup>14</sup>; and  
84

85           **WHEREAS**, the likelihood of children being exposed to PFAS increases as they  
86 come into contact with common household items, such as carpets and toys<sup>14</sup>; and  
87

88           **WHEREAS**, community water systems contaminated with PFAS  
89 disproportionately serve higher percentages of Hispanic/Latino and non-Hispanic Black  
90 populations and are located in watersheds with a greater number of PFAS sources<sup>15</sup>; and  
91

92           **WHEREAS**, Governor DeWine released Ohio’s first PFAS Action Plan in 2019,  
93 which aimed to sample public drinking water, identify PFAS contaminations in private  
94 water systems, establish drinking water action levels, and provide PFAS educational  
95 information to the public<sup>16</sup>; and

96  
97           **WHEREAS**, Ohio continued with the PFAS Action Plan 2.0, which revises Action  
98 Levels for drinking water and expands Ohio’s focus on PFAS through enhanced sampling,  
99 investigations, funding, and monitoring<sup>17</sup>; and

100  
101           **WHEREAS**, in June 2022, the U.S. Environmental Protection Agency (EPA)  
102 issued interim updated drinking water health advisories for perfluorooctanoic acid (PFOA)  
103 and perfluorooctane sulfonic acid (PFOS) at 4 parts per quadrillion due to their potential  
104 adverse health effects even at very low exposure levels, and final advisories for GenX  
105 Chemicals and perfluorobutane sulfonic acid (PFBS)<sup>18</sup>; and

106  
107           **WHEREAS**, in April 2024, the EPA finalized National Primary Drinking Water  
108 Regulations for six PFAS compounds, including Maximum Contaminant Levels (MCLs)  
109 of 4 parts per trillion for PFOA and PFOS, individual MCLs of 10 ppt for perfluorononanoic  
110 acid (PFNA), perfluorohexane sulfonic acid (PFHxS), hexafluoropropylene oxide dimer  
111 acid (HFPO-DA), as well as a Hazard Index MCL for mixtures containing PFHxS, PFNA,  
112 HFPO-DA, and PFBS<sup>18</sup>; and

113  
114           **WHEREAS**, in November 2024, the EPA released its three-year progress report  
115 on the PFAS Strategic Roadmap, highlighting advancements in their goals to protect  
116 drinking water, address PFAS contamination, improve chemical safety, protect lakes,  
117 rivers, and other water bodies, and expand PFAS-related research<sup>19</sup>; and

118  
119           **WHEREAS**, the American Medical Association (AMA) supports continued  
120 research on the impact of perfluoroalkyl and polyfluoroalkyl chemicals on human health<sup>20</sup>;  
121 and

122  
123           **WHEREAS**, the AMA advocates for states to follow guidelines presented in the  
124 EPA’s Drinking Water Health Advisories for PFOA and PFOS, with consideration of the  
125 appropriate use of Minimal Risk Levels<sup>20</sup>; and

126  
127           **WHEREAS**, our OSMA currently supports investigating endocrine-disrupting  
128 chemical substances that are in food, agriculture, and household products<sup>21</sup>; and  
129 therefore be it

130  
131           **RESOLVED**, that our OSMA supports continued research on the impact of  
132 perfluoroalkyl and polyfluoroalkyl chemicals on human health; and be it further

133  
134           **RESOLVED**, that our OSMA will amplify physician and public education around  
135 the adverse health effects of PFAS chemicals and potential mitigation and prevention  
136 efforts; and be it further

137

138 **RESOLVED**, that our OSMA will advocate, at minimum, for guidelines presented  
139 in the Environmental Protection Agency's Drinking Water Health Advisories; and be it  
140 further

141  
142 **RESOLVED**, that our OSMA encourages the integration of environmental health  
143 advocacy into clinical practice by encouraging physicians to be informed regarding risks  
144 of PFAS exposure on patient health.

145  
146 Fiscal Note: \$500+ (Sponsor)  
147 \$50,000 (Staff)

148  
149 **References:**

- 150 1. Per- and Polyfluoroalkyl Substances (PFAS). U.S. Food and Drug Administration.  
151 2025 Jan 03. [https://www.fda.gov/food/environmental-contaminants-food/and-](https://www.fda.gov/food/environmental-contaminants-food/and-polyfluoroalkyl-substances-pfas#:~:text=Per%2D%20and%20polyfluoroalkyl%20substances%20(PFAS)%20are%20chemicals%20that%20resist,oil%2C%20water%2C%20and%20heat)  
152 [polyfluoroalkyl-substances-](https://www.fda.gov/food/environmental-contaminants-food/and-polyfluoroalkyl-substances-pfas#:~:text=Per%2D%20and%20polyfluoroalkyl%20substances%20(PFAS)%20are%20chemicals%20that%20resist,oil%2C%20water%2C%20and%20heat)  
153 [pfas#:~:text=Per%2D%20and%20polyfluoroalkyl%20substances%20\(PFAS\)%20](https://www.fda.gov/food/environmental-contaminants-food/and-polyfluoroalkyl-substances-pfas#:~:text=Per%2D%20and%20polyfluoroalkyl%20substances%20(PFAS)%20are%20chemicals%20that%20resist,oil%2C%20water%2C%20and%20heat)  
154 [are%20chemicals%20that%20resist,oil%2C%20water%2C%20and%20heat](https://www.fda.gov/food/environmental-contaminants-food/and-polyfluoroalkyl-substances-pfas#:~:text=Per%2D%20and%20polyfluoroalkyl%20substances%20(PFAS)%20are%20chemicals%20that%20resist,oil%2C%20water%2C%20and%20heat)
- 155 2. Chemicals: Per- and Polyfluoroalkyl (PFAS) Substances. Wisconsin Department  
156 of Health Services. 2024 Dec 19.  
157 <https://www.dhs.wisconsin.gov/chemical/pfas.htm>
- 158 3. Bonato M, Corrà F, Bellio M, Guidolin L, Tallandini L, Irato P, Santovito G. PFAS  
159 Environmental Pollution and Antioxidant Responses: An Overview of the Impact  
160 on Human Field. *Int J Environ Res Public Health*. 2020 Oct 30;17(21):8020. doi:  
161 10.3390/ijerph17218020. PMID: 33143342; PMCID: PMC7663035.
- 162 4. PFAS in Drinking Water. Ohio Department of Health. 2024 Aug.  
163 [https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-](https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-0ac6e457dec8/Factsheet_PFAS+in+Drinking+Water_2023.05.05+%281%29.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_79GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-oxNZ8M0)  
164 [0ac6e457dec8/Factsheet\\_PFAS+in+Drinking+Water\\_2023.05.05+%281%29.pdf](https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-0ac6e457dec8/Factsheet_PFAS+in+Drinking+Water_2023.05.05+%281%29.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_79GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-oxNZ8M0)  
165 [?MOD=AJPERES&CONVERT\\_TO=url&CACHEID=ROOTWORKSPACE.Z18\\_7](https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-0ac6e457dec8/Factsheet_PFAS+in+Drinking+Water_2023.05.05+%281%29.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_79GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-oxNZ8M0)  
166 [9GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-](https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-0ac6e457dec8/Factsheet_PFAS+in+Drinking+Water_2023.05.05+%281%29.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_79GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-oxNZ8M0)  
167 [oxNZ8M0](https://odh.ohio.gov/wps/wcm/connect/gov/ede25510-d92b-4d6b-b6d1-0ac6e457dec8/Factsheet_PFAS+in+Drinking+Water_2023.05.05+%281%29.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_79GCH8013HMOA06A2E16IV2082-ed25510-d92b-4d6b-b6d1-0ac6e457dec8-oxNZ8M0)
- 168 5. Calvert L, Green MP, De Iulii GN, Dun MD, Turner BD, Clarke BO, Eamens AL,  
169 Roman SD, Nixon B. Assessment of the Emerging Threat Posed by  
170 Perfluoroalkyl and Polyfluoroalkyl Substances to Male Reproduction in Humans.  
171 *Front Endocrinol (Lausanne)*. 2022 Mar 9;12:799043. doi:  
172 10.3389/fendo.2021.799043. PMID: 35356147; PMCID: PMC8959433.
- 173 6. Per- and Polyfluoroalkyl Substances (PFAS) Report. Joint Subcommittee (JSC)  
174 on Environment, Innovation, and Public Health Per- and Polyfluoroalkyl  
175 Substances Strategy Team of the National Science and Technology Council.  
176 2023 March. [https://www.whitehouse.gov/wp-content/uploads/2023/03/OSTP-](https://www.whitehouse.gov/wp-content/uploads/2023/03/OSTP-March-2023-PFAS-Report.pdf)  
177 [March-2023-PFAS-Report.pdf](https://www.whitehouse.gov/wp-content/uploads/2023/03/OSTP-March-2023-PFAS-Report.pdf)
- 178 7. PFAS - Per- and Polyfluoroalkyl Substances. U.S. Department of Veteran Affairs.  
179 2024 Sep 30. <https://www.publichealth.va.gov/exposures/pfas.asp>
- 180 8. Xie MY, Lin ZY, Sun XF, Feng JJ, Mai L, Wu CC, Huang GL, Wang P, Liu YW,  
181 Liu LY, Zeng EY. Per- and polyfluoroalkyl substances (PFAS) exposure in  
182 plasma and their blood-brain barrier transmission efficiency-A pilot study. *Environ*

- 183 Int. 2024 May;187:108719. doi: 10.1016/j.envint.2024.108719. Epub 2024 May 6.  
184 PMID: 38718677.
- 185 9. Peritore AF, Gugliandolo E, Cuzzocrea S, Crupi R, Britti D. Current Review of  
186 Increasing Animal Health Threat of Per- and Polyfluoroalkyl Substances (PFAS):  
187 Harms, Limitations, and Alternatives to Manage Their Toxicity. International  
188 Journal of Molecular Sciences. 2023; 24(14):11707.  
189 <https://doi.org/10.3390/ijms241411707>
- 190 10. Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, Smith JS, Roberts  
191 SM. Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review:  
192 Current State of Knowledge and Strategies for Informing Future Research.  
193 Environ Toxicol Chem. 2021 Mar;40(3):606-630. doi: 10.1002/etc.4890. Epub  
194 2020 Dec 7. PMID: 33017053; PMCID: PMC7906952.
- 195 11. Clinical Evaluation and Management: PFAS Information for Clinicians. Agency  
196 for Toxic Substances and Disease Registry. 2024 Nov 12.  
197 [https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-  
198 management.html?CDC\\_AAref\\_Val=https://www.atsdr.cdc.gov/pfas/resources/pf  
199 as-information-for-clinicians.html](https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-management.html?CDC_AAref_Val=https://www.atsdr.cdc.gov/pfas/resources/pfas-information-for-clinicians.html)
- 200 12. PFAS Exposure Assessments Final Report. Agency for Toxic Substances and  
201 Disease Registry. 2022 Sep 22. [https://www.atsdr.cdc.gov/pfas/docs/PFAS-EA-  
202 Final-Report-508.pdf](https://www.atsdr.cdc.gov/pfas/docs/PFAS-EA-Final-Report-508.pdf)
- 203 13. PFAS Information for Clinicians - 2024. Agency for Toxic Substances and  
204 Disease Registry. 2024 Nov 12. [https://www.atsdr.cdc.gov/pfas/hcp/clinical-  
205 overview/?CDC\\_AAref\\_Val=https://www.atsdr.cdc.gov/pfas/resources/pfas-  
206 information-for-clinicians.html](https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/?CDC_AAref_Val=https://www.atsdr.cdc.gov/pfas/resources/pfas-information-for-clinicians.html)
- 207 14. Our Current Understanding of the Human Health and Environmental Risks of  
208 PFAS. United States Environmental Protection Agency. 2024 Nov 26.  
209 [https://www.epa.gov/pfas/our-current-understanding-human-health-and-  
210 environmental-risks-pfas](https://www.epa.gov/pfas/our-current-understanding-human-health-and-environmental-risks-pfas)
- 211 15. Liddie JM, Schaider LA, Sunderland EM. Sociodemographic Factors Are  
212 Associated with the Abundance of PFAS Sources and Detection in U.S.  
213 Community Water Systems. Environ Sci Technol. 2023 May 30;57(21):7902-  
214 7912. doi: 10.1021/acs.est.2c07255. Epub 2023 May 15. PMID: 37184106;  
215 PMCID: PMC10233791.
- 216 16. Eagle J. Ohio and EPA Department of Health Issue PFAS Action Plan for 2020  
217 Implementation. Thompson Hine. 2019 Dec 09.  
218 [https://www.thompsonhine.com/insights/ohio-epa-and-department-of-health-  
219 issue-pfas-action-plan-for-2020-implementation/](https://www.thompsonhine.com/insights/ohio-epa-and-department-of-health-issue-pfas-action-plan-for-2020-implementation/)
- 220 17. Ohio's PFAS Action Plan. Ohio Environmental Protection Agency.  
221 [https://epa.ohio.gov/monitor-pollution/pollution-issues/per-and-polyfluoroalkyl-  
222 substances-pfas](https://epa.ohio.gov/monitor-pollution/pollution-issues/per-and-polyfluoroalkyl-substances-pfas)
- 223 18. Environmental Protection Agency: PFAS National Primary Drinking Water  
224 Regulation. U.S. Government Accountability Office. 2024 May 13.  
225 <https://www.gao.gov/products/b-336287>
- 226 19. EPA's PFAS Strategic Roadmap: Three Years of Progress. United States  
227 Environmental Protection Agency. 2024 Nov.

- 228 [https://www.epa.gov/system/files/documents/2024-11/epas-pfas-strategic-](https://www.epa.gov/system/files/documents/2024-11/epas-pfas-strategic-roadmap-2024_508.pdf)  
229 [roadmap-2024\\_508.pdf](https://www.epa.gov/system/files/documents/2024-11/epas-pfas-strategic-roadmap-2024_508.pdf)  
230 20. Per- and Polyfluoroalkyl Substances (PFAS) and Human Health H-135.916.  
231 American Medical Association. 2024. [https://policysearch.ama-](https://policysearch.ama-assn.org/policyfinder/detail/H-135.916%20?uri=%2FAMADoc%2FHOD.xml-H-135.916.xml)  
232 [assn.org/policyfinder/detail/H-135.916%20?uri=%2FAMADoc%2FHOD.xml-H-](https://policysearch.ama-assn.org/policyfinder/detail/H-135.916%20?uri=%2FAMADoc%2FHOD.xml-H-135.916.xml)  
233 [135.916.xml](https://policysearch.ama-assn.org/policyfinder/detail/H-135.916%20?uri=%2FAMADoc%2FHOD.xml-H-135.916.xml)  
234 21. Policy 7 – 2023 -- Establishing Support for the Regulation of Endocrine  
235 Disrupting Chemicals in Food, Agricultural, and Household Products. OSMA  
236 Policy Compendium Policies of the OSMA House of Delegates. 2024 April.  
237 [https://osma.org/aws/OSMA/asset\\_manager/get\\_file/366536?ver=2041](https://osma.org/aws/OSMA/asset_manager/get_file/366536?ver=2041)

## 238 **RELEVANT OSMA POLICY**

### 239 240 **Policy 7 – 2023 – Establishing Support for the Regulation of Endocrine Disrupting** 241 **Chemicals in Food, Agricultural, and Household Products**

242 OSMA supports the investigation and regulation of the use of endocrine-disrupting  
243 chemicals in food, agricultural, and household products.  
244

### 245 **Policy 03 – 2018 – Pursuit of a Strategic Partnership with the Ohio Public Health** 246 **Association**

247 1. The OSMA create a formal partnership, establishing an open line of communication,  
248 with the Ohio Public Health Association for medical students and physicians. 2. The  
249 OSMA support policies and initiatives that may, based on reasonable evidence, produce  
250 population health improvements, as well as incentivize healthcare providers, hospitals,  
251 clinics, and other healthcare facilities to engage in health promotion  
252

## 253 **RELEVANT AMA POLICY**

### 254 **H-135.916 – Per- and Polyfluoroalkyl Substances (PFAS) and Human Health**

255 1. Our American Medical Association supports continued research on the impact of  
256 perfluoroalkyl and polyfluoroalkyl chemicals on human health. 2. Our AMA supports  
257 legislation and regulation seeking to address contamination, exposure, classification,  
258 and clean-up of PFAS substances. 3. Our AMA will advocate for states, at minimum, to  
259 follow guidelines presented in the Environmental Protection Agency's Drinking Water  
260 Health Advisories for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid  
261 (PFOS), with consideration of the appropriate use of Minimal Risk Levels (MRLs)  
262 presented in the CDC/ATSDR Toxicological Profile for PFAS. 4. Our AMA will amplify  
263 physician and public education around the adverse health effects of PFAS chemicals  
264 and potential mitigation and prevention efforts.  
265

### 266 **H-135.939 – Green Initiatives and the Health Care Community**

267 Our AMA supports: (1) responsible waste management and clean energy production  
268 policies that minimize health risks, including the promotion of appropriate recycling and  
269 waste reduction; (2) the use of ecologically sustainable products, foods, and materials  
270 when possible; (3) the development of products that are non-toxic, sustainable, and  
271 ecologically sound; (4) building practices that help reduce resource utilization and  
272 contribute to a healthy environment; (5) the establishment, expansion, and continued  
273 maintenance of affordable, accessible, barrier-free, reliable, and clean-energy public

274 transportation; and (6) community-wide adoption of 'green' initiatives and activities by  
275 organizations, businesses, homes, schools, and government and health care entities.

1 OHIO STATE MEDICAL ASSOCIATION HOUSE OF DELEGATES  
2 2025 OSMA Policy Sunset Report  
3

4 **Introduced by:** OSMA Council  
5 **Subject:** 2025 OSMA Policy Sunset Report  
6 **Referred to:** Resolutions Committee 1  
7 -----  
8

9 **WHEREAS**, Chapter 5, Section 14 of the Ohio State Medical Association Constitution  
10 and Bylaws provides that: any resolution/policy adopted by the House of Delegates four (4) or  
11 more years prior to each Annual Meeting will be reviewed by the Council for purposes of  
12 recommending whether to retain each policy. The House of Delegates will be notified of those  
13 policies subject to review prior to the Annual Meeting at which they will be considered. Any  
14 policy not retained by House action on the report submitted by the Council becomes null, void  
15 and of no effect; and therefore  
16

17 **BE IT RESOLVED**, that the recommendations of OSMA Council published prior to the  
18 Annual Meeting as the 2025 OSMA Policy Sunset Report be adopted by the OSMA House of  
19 Delegates.  
20

21 **Ohio State Medical Association Policy Compendium Review –**

22 **2025 OSMA Policy Sunset Report**

23 **OSMA policy from years 1932 through the 2024 Sunset Report**  
24

25 *(This is a list of Policy numbers and titles. The full text of policies recommended*  
26 *“RETAIN” as edited and “NOT RETAIN” is contained in this report. All other OSMA*  
27 *policies will be retained as they are shown in the OSMA Policy Compendium available on*  
28 *[www.osma.org](http://www.osma.org).)*  
29  
30

31 **Policies to be Retained as Edited:**

32 None  
33

34 **Policies to be Not Retained:**

35 Policy 1 – 2023- Establish a Women Physician Section and Senior Physician Section  
36 Policy 2 – 2023- Establish the OSMA Membership Task Force as an OSMA Standing  
37 Committee  
38  
39

40  
41 **Full text of policies recommended “RETAIN” as Edited and “NOT RETAIN”**  
42

Recommendation	Policy	Comment
<b>NOT RETAIN</b>	<b>Policy 1 – 2023- Establish a Women Physician Section and Senior Physician Section</b>	Accomplished

Recommendation	Policy	Comment
	1. OSMA Constitution and Bylaws are amended to establish a Women and Senior Section.	
<b>NOT RETAIN</b>	<p><b>Policy 2 – 2023 -- Establish the OSMA Membership Task Force as an OSMA Standing Committee</b></p> <p>1. OSMA Constitution and Bylaws are amended to establish the Standing Committee on Membership.</p>	Accomplished

43

44 **Fiscal Note:** \$0 (Sponsor)

45 \$0 (Staff)